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BISHYDRAZONE-BASED ANTIFUNGAL 
AGENTS 
RELATED APPLICATIONS 
This application claims the benefit of U.S. Provisional 
Application Ser. No. 62/359,487, filed Jul. 7, 2016, the entire 
disclosure of which is incorporated herein by this reference. 
2 
protozoan diseases, such as Trypanosoma brucei gambiense 
(West African trypanosomiasis) as well as systemic fungal 
infections caused by Pneumocystis jirovecii, often seen in 
patients with HIV. Related compounds include symmetrical 
bisamidines, ( e.g., furimidazoline ), developed principally as 
topoisomerase inhibitors for cancer treatments. In addition 
to these biscationic compounds, other hydrazone- and guani-
dine-containing molecules possess a range of promising 
biological activities including antituberculosis, anti-HIV, 
GOVERNMENT INTEREST 1 o anticonvulsant, anticancer, anti-inflammatory, antimalarial, 
antibacterial, and antifungal activities. Recently, bis(N-ami-
dino)hydrazones were reported to inhibit the calcium-de-
pendent serine endoprotease, furin, which activates imma-
This invention was made with govermnent support by 
NIH grant A1090048 and NIH grants UOl DA013519, 
UL1TR000117 and T32 DA016176; and NIH grants P20 
RR020171, CA172379 and CA187273. The Government 15 
has certain rights in the invention. 
TECHNICAL FIELD 
The present disclosure is directed to hydrazone com- 20 
pounds and pharmaceutical compositions including same 
having antifungal activity and methods for treating or pre-
venting fungal conditions in a subject in need thereof by 
administering same. 
ture proteins to their functional, mature form. 
Accordingly, a continuing need exists for the develop-
ment of specific antifungal agents for the treatment and 
prevention of fungal diseases and infections. 
SUMMARY 
The presently-disclosed subject matter meets the above-
identified needs, as will become evident to those of ordinary 
skill in the art after a study of information provided in this 
document. Advantages of the present disclosure include 
BACKGROUND 
25 antifungal agents and pharmaceutical compositions includ-
ing same for the treatment or prevention of a fungal condi-
tion in a subject in need thereof. 
The emergence of multidrug-resistant bacteria and fungi This summary describes several embodiments of the 
presently-disclosed subject matter, and in many cases lists as human pathogens warrants a continued focus on the 
development of new pharmacophores for the treatment of 
these devastating and often fatal infections. The rise of 
multidrug-resistant bacteria, such as methicillin-resistant 
Staphylococcus aureus (MRSA) and vancomycin-resistant 
Enterococci (VRE), adversely affects the efficacy of many 
known, standard-of-care, antibacterial agents. Evidence of 
the impact of these multidrug-resistant strains appears in a 
2011 report from the Centers for Disease Control and 
Prevention (CDC) that estimates that the national incidence 
30 variations and permutations of these embodiments. This 
s=ary is merely exemplary of the numerous and varied 
embodiments. Mention of one or more representative fea-
tures of a given embodiment is likewise exemplary. Such an 
embodiment can typically exist with or without the 
35 feature(s) mentioned; likewise, those features can be applied 
to other embodiments of the presently-disclosed subject 
matter, whether listed in this summary or not. To avoid 
excessive repetition, this summary does not list or suggest 
of invasive MRSA infections was 80,461 cases and 650 
deaths. This mortality rate is among the highest recorded for 40 
bacterial infections. Likewise, listerosis, which is a common 
foodborne illness caused by Listeria monocytogenes, repre-
sents a serious illness afflicting elderly people, newborns, 
and those with impaired immune systems. Estimates suggest 
that L. monocytogenes causes 19% of deaths associated with 45 
the consumption of contaminated foods in the United States. 
The incidence of invasive fungal infections is also on the 
rise due to an increasing population of critically ill patients 
as a result of the human immunodeficiency virus (HIV), 
systemic diseases such as cancer, and the increasing role of 50 
organ transplantation. The National Healthcare Safety Net-
work (NHSN) at the CDC has reported that Candida spp. 
ranked fifth among hospital-acquired pathogens. Candida 
spp. fungi have also been reported as the fourth most 
common causative pathogens of nosocomial, often fatal 55 
bloodstream infections. Eukaryotic C. albicans share a close 
evolutionary relationship as well as many cellular mecha-
nisms with their human hosts and present therapeutic chal-
lenges for new treatments for systemic fungal infections. 
There is an unquestioned need for new antimicrobials that 60 
selectively inhibit these microorganisms without causing 
host toxicity. 
Pentamidine represents an archetypical, biscationic anti-
biotic with a symmetrical structure containing two ami-
dinium functional groups separated by a flexible 1,5-diphe- 65 
noxypentane spacer. Developed initially as an antiprotozoal 
agent, it currently finds applications in both the treatment of 
all possible combinations of such features. 
Provided herein, in some embodiments, is an antifungal 
composition comprising a compound according to formula 
(I): 
(I) 
R R 
R\ }-linker----( l 
HN-N N-NH 
or a pharmaceutically acceptable salt thereof, wherein each 
R is independently H or a lower alkyl, wherein each R 1 is 
independently an amidino or an aryl, and wherein the liuker 
comprises at least one aryl. In some embodiments, the liuker 
comprises a polycyclic aryl according to formula (II): 
(II) 
D-\\ -0 '/-~ Z1 \ j ------z ,,,, 
2' 
wherein Z1 is selected from the group consisting of a single 
bond between the phenyl groups, a lower alkyl linking the 
phenyl groups, a R3-Y-R3 group, a chalcogen, and com-
US 10,173,968 B2 
3 
binations thereof; wherein Z2 is selected from the group 
consisting of not present, a lower alkyl, a R3-Y-R3 group, 
-C(R4)-, ----C(R4 ) 2-, -N(Rs)-, or a combination 
thereof; wherein each R3 is independently a lower alkyl; 
wherein each R4 is independently H or a lower alkyl; 5 
wherein Rs is H or a lower alkyl; and wherein Y is a 
chalcogen. In some embodiments, the compound is a phar-
maceutically acceptable hydrochloride salt. 
In one embodiment, the compound is according to for-
mula (III): 10 
(III) 
NHR RHN 
R
2
HN-< }-linker----( }--NHR2 15 
HN-N N-NH 
4 
X is independently selected from the group consisting of 
fluorine, chlorine, and bromine. The compounds having 
formula (V) are referred to herein as N-amidino-N'-aryl-
bishydrazones. 
Also provided herein, in some embodiments, is a method 
for treating a fungal condition, the method comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound according to formula (I): 
(I) 
R R 
R\ }-linker----( l 
HN-N N-NH 
or a pharmaceutically acceptable salt thereof, wherein each 
R is independently H or a lower alkyl, wherein each R 1 is 
independently an amidino or an aryl, and wherein the linker or a pharmaceutically acceptable salt thereof; wherein each 
R2 is independently selected from the group consisting ofH, 
a lower alkyl, an aryl, a substituted lower alkyl, a substituted 
aryl, and combinations thereof. The compounds having 
formula (III) are referred to herein as bis(N-amidino)hydra-
zones. 
20 comprises at least one aryl. In some embodiments, the linker 
comprises a polycyclic aryl according to formula (II): 
In another embodiment, the compound is according to 
25 
formula (IV): 
(IV) 30 
(II) 
D-\\ -0 '/-~ Z1 \ j 
------z _,,' 
2' 
or a pharmaceutically acceptable salt thereof; wherein Ar is 
an aryl group; wherein each X is selected from the group 
consisting of electron-withdrawing groups such as, but not 
limited to, a halogen, a carbonyl group (e.g., -C(=O)R, 
-C(=O)OR, -C(=O)NR2 , or ----CH(=O)), sulfoxide, 
sulfone, sulfonate, sulfonamide, a nitro group, a cyano 
group, or a combination thereof; and wherein each n is 
independently between O and 5, with O representing an 
unsubstituted aryl group. In some embodiments, each X is 
independently selected from the group consisting of fluo-
rine, chlorine, and bromine. The compounds having formula 45 
(IV) are referred to herein as bis(N-aryl)hydrazones. 
wherein Z1 is selected from the group consisting of a single 
bond between the phenyl groups, a lower alkyl linking the 
phenyl groups, a R3-Y-R3 group, a chalcogen, and com-
binations thereof; wherein Z2 is selected from the group 
35 consisting of not present, a lower alkyl, a R3 -Y-R3 group, 
----C(R4)-, ----C(R4 ) 2-, -N(Rs)-, or a combination 
thereof wherein each R3 is independently a lower alkyl; 
wherein each R4 is independently H or a lower alkyl; 
wherein Rs is H or a lower alkyl; and wherein Y is a 
40 chalcogen. In some embodiments, the compound is a phar-
maceutically acceptable hydrochloride salt. 
In another embodiment, the compound is according to 
formula (V): 
(V) 
50 
In one embodiment, the compound is according to for-
mula (III): 
(III) 
NHR RHN 
R
2
HN-< }-linker----( }-NHR2 
HN-N N-NH 
or a pharmaceutically acceptable salt thereof; wherein each 
R2 is independently selected from the group consisting ofH, 
a lower alkyl, an aryl, a substituted lower alkyl, a substituted 
55 aryl, and combinations thereof. 
or a pharmaceutically acceptable salt thereof; wherein Ar is 
an aryl group; wherein each X is independently selected 
from the group consisting of electron-withdrawing groups 
such as, but not limited to, a halogen, a carbonyl group ( e.g., 60 
-C(=O)R, ----C(=O)OR, ----C(=)NR2 , or ----CH(=O)), 
sulfoxide, sulfone, sulfonate, sulfonamide, a nitro group, a 
cyano group, or a combination thereof; wherein n is between 
O and 5, with O representing an unsubstituted aryl group; and 
wherein R2 is selected from the group consisting of H, a 65 
lower alkyl, an aryl, a substituted lower alkyl, a substituted 
aryl, and combinations thereof. In some embodiments, each 
In another embodiment, the compound is according to 
formula (IV): 
(IV) 
or a pharmaceutically acceptable salt thereof; wherein Ar is 
an aryl group; wherein each X is selected from the group 
US 10,173,968 B2 
5 6 
C. After staining with DCFH-DA (20 µg/mL), the samples 
were analyzed using a Zeiss Axovert 200M fluorescence 
microscope. 
FIGS. 4A-B show graphs illustrating a mammalian cell 
cytotoxicity of selected bis(N-amidino )hydrazones and 
N-amidino-N-aryl-bishydrazones, as well as AmB (as a 
control) against (A) A549 cell line and (B) BEAS-2B cell 
line. 
consisting of electron-withdrawing groups such as, but not 
limited to, a halogen, a carbonyl group (e.g., -C(=O)R, 
-C(=O)OR, -C(=O)NR2 , or ----CH(=O)), sulfoxide, 
sulfone, sulfonate, sulfonamide, a nitro group, a cyano 
group, or a combination thereof; and wherein each n is 
independently between O and 5, with O representing an 
unsubstituted aryl group. In some embodiments, each X is 
independently selected from the group consisting of fluo-
rine, chlorine, and bromine. 
In another embodiment, the compound is according to 
formula (IV): 
FIG. 5 shows graphs illustrating IC50 curves for hERG 
10 inhibition by some representative bis(N-amidino )hydra-
zones and N-amidino-N-aryl-bishydrazones. 
(V) 
R R HN 
XnAr\ ~ linker--{ )--NHR2 
HN-N N-NH 
15 
DETAILED DESCRIPTION OF THE 
DISCLOSURE 
The details of one or more embodiments of the presently-
disclosed subject matter are set forth in this document. 
Modifications to embodiments described in this document, 
and other embodiments, will be evident to those of ordinary 
or a pharmaceutically acceptable salt thereof; wherein Ar is 
an aryl group; wherein each X is independently selected 
from the group consisting of electron-withdrawing groups 
such as, but not limited to, a halogen, a carbonyl group ( e.g., 
-C(=O)R, ----C(=O)OR, ----C(=O)NR2 , or ----CH(=O)), 
sulfoxide, sulfone, sulfonate, sulfonamide, a nitro group, a 
cyano group, or a combination thereof; wherein n is between 
20 skill in the art after a study of the information provided in 
this document. The information provided in this document, 
and particularly the specific details of the described exem-
plary embodiments, is provided primarily for clearness of 
understanding and no unnecessary limitations are to be 
25 understood therefrom. In case of conflict, the specification of 
this document, including definitions, will control. 
O and 5, with O representing an unsubstituted aryl group; and 
wherein R2 is selected from the group consisting of H, a 
lower alkyl, an aryl, a substituted lower alkyl, a substituted 
aryl, and combinations thereof. In some embodiments, each 30 
X is independently selected from the group consisting of 
fluorine, chlorine, and bromine. 
Additional advantages of the present invention will 
become readily apparent to those skilled in this art from the 
following detailed description, wherein only the preferred 35 
embodiment of the invention is shown and described, simply 
by way of illustration of the best mode contemplated of 
carrying out the invention. As will be realized, the invention 
is capable of other and different embodiments, and its 
several details are capable of modifications in various obvi- 40 
ous respects, all without departing from the invention. 
Accordingly, the drawings and description are to be regarded 
as illustrative in nature, and not as restrictive. 
While the terms used herein are believed to be well 
understood by those of ordinary skill in the art, certain 
definitions are set forth to facilitate explanation of the 
presently-disclosed subject matter. 
Unless defined otherwise, all technical and scientific 
terms used herein have the same meaning as is commonly 
understood by one of skill in the art to which the invention(s) 
belong. 
All patents, patent applications, published applications 
and publications, GenBank sequences, databases, websites 
and other published materials referred to throughout the 
entire disclosure herein, unless noted otherwise, are incor-
porated by reference in their entirety. 
Where reference is made to a URL or other such identifier 
or address, it understood that such identifiers can change and 
particular information on the internet can come and go, but 
equivalent information can be found by searching the inter-
net. Reference thereto evidences the availability and public 
BRIEF DESCRIPTION OF THE DRAWINGS 45 dissemination of such information. 
As used herein, the abbreviations for any protective 
groups, amino acids and other compounds, are, unless 
indicated otherwise, in accord with their common usage, 
recognized abbreviations, or the IUPAC-IUB Commission 
FIGS. lA-B show schematic views of processes for 
synthesizing compounds of the present disclosure. (A) is a 
synthetic scheme for the preparation of bis(N-amidino) 
hydrazones according to embodiments of the present dis-
closure. (B) is a synthetic scheme for the preparation of 
bis(N-aryl)hydrazones and N-amidino-N'-aryl-bishydra-
zones according to embodiments of the present disclosure. 
50 on Biochemical Nomenclature (see, Biochem. (1972) 11(9): 
1726-1732). 
FIG. 2 is a bar graph showing the changes in MIC values 
of L. monocytogenes ATCC 19115 (strain B), MRSA (strain 
C), VRE (strain D), and P. aeruginosa ATCC 27853 (strain 
Although any methods, devices, and materials similar or 
equivalent to those described herein can be used in the 
practice or testing of the presently-disclosed subject matter, 
55 representative methods, devices, and materials are described 
herein. 
I) treated previously with AMK (green), 7Aa (purple), 4F 
(blue), 4D (orange), as well as C. albicans ATCC 10231 
treated previously withAmB (yellow), 7Aa (purple), and 4F 
(blue) over 15 cycles. Numbers above the bars represent the 60 
passage number when either bacterial or fungal cells devel-
oped resistance. 
FIG. 3 shows images illustrating the effect of compounds 
4F and 7Aa on intracellular ROS production by C. albicans 
ATCC 10231. Yeast cells were treated with no drug (nega- 65 
tive control), 1 mM of H2 0 2 (positive control), or 4F and 
7 Aa, at their 1 x and 2x respective MIC values for 1 hat 35° 
Following long-standing patent law convention, the terms 
"a", "an", and "the" refer to "one or more" when used in this 
application, including the claims. Thus, for example, refer-
ence to "a cell" includes a plurality of such cells, and so 
forth. 
Unless otherwise indicated, all numbers expressing quan-
tities of ingredients, properties such as reaction conditions, 
and so forth used in the specification and claims are to be 
understood as being modified in all instances by the term 
"about". Accordingly, unless indicated to the contrary, the 
numerical parameters set forth in this specification and 
US 10,173,968 B2 
7 
claims are approximations that can vary depending upon the 
desired properties sought to be obtained by the presently-
disclosed subject matter. 
As used herein, the term "about," when referring to a 
value or to an amount of mass, weight, time, volume, 5 
concentration or percentage is meant to encompass varia-
tions of in some embodiments ±20%, in some embodiments 
±10%, in some embodiments ±5%, in some embodiments 
±1%, in some embodiments ±0.5%, and in some embodi-
ments ±0.1 % from the specified amount, as such variations 
10 
are appropriate to perform the disclosed method. 
8 
or a pharmaceutically acceptable salt thereof. For formula 
(I), each R is independently H or a lower alkyl, e.g., a C1 _6 
alkyl such as a methyl or ethyl group. In one embodiment, 
each R1 is independently an amidino (----C( NH)NH2 ) or 
an aryl group. In another embodiment, at least one R1 is 
independently substituted with one or more electron-with-
drawing groups such as, but not limited to, one or more 
halogens, one or more carbonyl groups (e.g., ----C(=O)R, 
----C(=O)OR, ----C(=O)NR2 , or ----CH(=O)), one or more 
sulfoxide, one or more sulfone, one or more sulfonate, one 
or more sulfonamide, one or more nitro groups, one or more 
cyano groups, or a combination thereof. As used herein, ranges can be expressed as from "about" 
one particular value, and/or to "about" another particular 
value. It is also understood that there are a number of values 
disclosed herein, and that each value is also herein disclosed 
as "about" that particular value in addition to the value itself. 
For example, if the value "10" is disclosed, then "about 10" 
is also disclosed. It is also understood that each unit between 
two particular units are also disclosed. For example, if 10 
and 15 are disclosed, then 11, 12, 13, and 14 are also 
disclosed. 
The linker group of formula (I) includes any suitable 
moiety having at least one aryl group. For example, in one 
embodiment, the linker group includes a single aryl, radical, 
15 substituted aryl, or aryl derivative. Suitable single aryl linker 
groups include, but are not limited to: 
20 
As used herein, the term "aryl" or "aryl group" refers to 
a substituent derived from an aromatic ring, including, but 
not limited to, a phenyl group, pyridyl and other heterocyclic 
variants, and/or naphthyl and other polycyclic variants. The 
term "substituted aryl" or "substituted aryl group," as used 25 
herein, refers to an aryl group where one or more hydrogen 
atoms has been replaced by an electron-withdrawing group. 
Unless stated otherwise, use of the term "aryl" or "aryl 
group" is intended to include "substituted aryl" or "substi-
tuted aryl group" throughout the instant disclosure. 
30 The term "treat" and "treatment" refer to both therapeutic 
treatment and prophylactic or preventative measures, 
wherein the object is to prevent or slow down (lessen) an 
undesired pathological change or disorder, such as the 
development or spread of fungi. For purpose of this disclo-
sure, beneficial or desired clinical results include, but are not 35 
limited to, alleviation of symptoms, diminishment of extent 
of disease, stabilized (i.e., not worsening) state of disease, 
delay or slowing of disease progression, amelioration or 
palliation of the disease state, and remission (whether partial 
In another embodiment, the linker group is a polycyclic 
aryl according to formula (II): 
(II) 
where Z2 is optionally present in the linker group. Z1 is a 
single bond between the phenyl groups, a lower alkyl linking 
the phenyl groups (e.g., a C1 _6 alkyl), a R
3-Y-R3 group, 
a chalcogen (e.g., S; 0), or a combination thereof. Z2 , when 
present, is a lower alkyl (e.g., a C1 _6 alkyl), R
3-Y-R3 
group, -C(R4)-, -C(R4 ) 2-, -N(R
5
)-, or a combina-
tion thereof. Each R3 is independently a lower alkyl (e.g., a 
C1_6 alkyl). Each R
4 is independently H or a lower alkyl 
or total), whether detectable or undetectable. "Treatment" 40 
can also mean prolonging survival as compared to expected 
survival if not receiving treatment. Those in need of treat-
ment include those already with the condition or disorder as 
well as those prone to have the condition or disorder or those 
45 (e.g., a C1_6 alkyl). R
5 is H or a lower alkyl (e.g., a C1 _6 
alkyl). Y is a chalcogen, e.g., 0, S. Suitable linker groups 
according to formula (II) include, but are not limited to: 
in which the condition or disorder is to be prevented. 
The presently-disclosed subject matter includes antifun-
gal compounds having antifungal activity and pharmaceu-
tical compositions including such compounds together with 
a pharmaceutically acceptable carrier. The antifungal com-
pounds of the present disclosure are useful as antifungal 50 
agents and can inhibit the growth and reproduction of fungal 
cells and/or decrease the number of fungi. Accordingly, the 
antifungal compounds of the present disclosure can be used 
to treat or prevent a fungal condition, e.g., a fungal disease 
or infection, in a subject in need thereof. Subject as used 55 
herein refer to mammals and in particular to humans and 
domestic animals. 
The antifungal compound of the instant disclosure 
includes a bishydrazone of the general formula (I): 
(I) 
R R 
R\ }-linker--{ l 
HN-N N-NH 
60 
65 
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-continued 
P
0
Dt 
As will be understood by those skilled in the art, suitable 
linker groups are not limited to the specific examples above 
and may include any other structure or conformation encom-
passed by formula (II). 
In some embodiments, each R 1 in the hydrazone of 
formula (I) is an amidino or substituted amidino group, 
according to formula (III): 
(III) 
NHR RHN 
R
2
HN---< }-linker---{ }-NHR2 
HN-N N-NH 
10 
15 
30 
35 
40 
45 
50 
or a pharmaceutically acceptable salt thereof. For formula 
(III), each R is selected as described above with respect to 
formula (I). Additionally, each R2 is independently H; a 
lower alkyl; an aryl; a substituted lower alkyl including, but 
not limited to, -CH2X, CH2CH2X, or ----CH2 CH2CH2X, 
where X includes fluorine, alkoxy (OR), or amino (e.g., 
NHR or NR2); a substituted aryl; or a combination thereof. 65 
Suitable compounds according to formula (III) include, but 
are not limited to: 
HN==<NH2 
HN-N 
~ 
NH2 
HNANH.,.N~ 
H 
NH2 
HN==< 
HN-N 
' 
10 
H 
_N NH2, 
\H----< 
NH 
NH2 
"""N'NHANH, 
H 
~ 
N-HN 
>=NH, 
In other embodiments, each R 1 in the bishydrazone of 
formula (I) is an aryl or substituted aryl, according to 
formula (IV): 
US 10,173,968 B2 
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(IV) 
or a pharmaceutically acceptable salt thereof. For formula 
(IV), each R is selected as described above with respect to 
formula (I). Ar is an aryl group (e.g., a phenyl group or a 
substituted phenyl group); X is an electron-withdrawing 
group such as, but not limited to, a halogen (e.g., fluorine, 
chlorine, bromine, iodine), a carbonyl group ( e.g., ----C(=O) 
12 
R, ----C(=O)OR, -C(=O)NR2 , or-CH(=O)), sulfoxide, 
sulfone, sulfonate, sulfonamide, a nitro group, a cyano 
group, or a combination thereof; and n represents the num-
ber of such electron-withdrawing groups on the aryl group, 
5 which can be O to 5, with O representing an unsubstituted 
aryl group. In one embodiment, for example, at least one of 
the aryl groups is substituted with one or more fluoro or one 
or more chloro groups, or both e.g., a fluorinated, chlori-
nated, difluorinated, dichlorinated, or fluoro-chloro substi-
10 tuted aryl group such as a halogenated phenyl group. Suit-
able compounds according to formula (IV) include, but are 
not limited to: 
Fu yCCSDy 0 F. I N I I N I ~ N/ ~ ,;;:?' N ,;;:?' 7" '-N ~ 
H I H 
H CH3 H 
H 
H 
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c,D N ,(Ye, ,::::;" '-N ~ 
I N 
H 
~ N/ 's::::, H 
H 
H 
~/ 
and 
"Y 
N 
I N 
,::::;" '1i 
~ 1i/ 's::::: H F 
F H 
F 
F 
PN'NDF FDN/N~ H H 
H 
H 
Alternatively, in some embodiments, one R1 in the hydra- 30 
zone of formula (I) is an amidino or substitute amidino, and 
the other R1 is an aryl or substituted aryl, according to 
formula (V): 
erature. Additionally, in some embodiments, the compounds 
disclosed herein provide antimicrobial activity without or 
substantially without developing drug resistance. Further-
more, in some embodiments, the compounds disclosed 
herein increase reactive oxygen species (ROS) production. 
(V) 
R R HN 
XnAr\ }--linker--{ )----NHR
2 
HN-N N-NH 
or a pharmaceutically acceptable salt thereof. For formula 
(V), each R is selected as described above with respect to 
formula (I). Ar is an aryl group (e.g., a phenyl group); Xis 
an electron-withdrawing group such as, but not limited to, a 
halogen ( e.g., fluorine, chlorine, bromine, iodine), a carbo-
nyl group (e.g., -C(=O)R, -C(=O)OR, ----C(=O)NR2 , 
or ----CH(=O)), sulfoxide, sulfone, sulfonate, sulfonamide, 
a nitro group, cyano group, or a combination thereof; and n 
represents the number of such electron-withdrawing groups 
on the aryl group, which can be O to 5, with O representing 
an unsubstituted aryl group. R2 is H; a lower alkyl; an aryl; 
a substituted lower alkyl including, but not limited to, 
-CH2X, CH2 CH2X, or -CH2CH2 CH2X, where X 
includes fluorine, alkoxy (OR), or amino (e.g., NHR or 
NR2 ); a substituted aryl; or a combination thereof. 
The compounds of formula (I) including a linker group 
according to one or more of the embodiments disclosed 
herein provide increased antibacterial and/or antifungal 
activities as compared to existing compounds. For example, 
35 Accordingly, in some embodiments, the present disclo-
sure includes methods for treating a fungal condition, e.g., a 
fungal disease, or fungal infection, by administering to a 
subject in need thereof a therapeutically effective amount of 
a compound according to formula (I), a pharmaceutically 
acceptable salt thereof, or a pharmaceutically acceptable 
40 composition including a compound according to formula (I) 
or a pharmaceutically acceptable salt thereof together with a 
pharmaceutically acceptable carrier. For example, in one 
embodiment, the method for treating a fungal condition 
includes administering to a subject in need thereof a thera-
45 peutically effective amount of a compound according to any 
one or more of formulae (III)-(V), pharmaceutically accept-
able salts thereof, or a pharmaceutically acceptable compo-
sition including one or more compounds according to for-
mulae (III)-(V) or pharmaceutically acceptable salts thereof 
50 together with a pharmaceutically acceptable carrier. 
The phrase "therapeutically effective amount" means an 
amount of a compound of the present disclosure that (1) 
treats or prevents the particular disease, condition, or dis-
order, (2) attenuates, ameliorates, or eliminates one or more 
55 
symptoms of the particular disease, condition, or disorder, or 
(3) prevents or delays the onset of one or more symptoms of 
the particular disease, condition, or disorder described 
herein. In the case of fungal infection, the therapeutically 
effective amount of the drug may be to inhibit the growth 
and/or reproduction of fungal cells and/or decrease the 
60 number of fungi and/or relieve to some extent one or more 
of the symptoms associated with a fungal condition such as 
a fungal disease or infection in a subject. 
in one embodiment, biscationic pharmacophores, such as the 
bis(N-amidino )hydrazones, bis(N-aryl)hydrazones, or 
N-amidino-N'-aryl-bishydrazones disclosed herein, with 
either a flexible or a rigid spacer, provide increased anti-
bacterial and antifungal activities as compared to existing 65 
flexible bisamidines, as well as existing hydrazone- and 
guanidine-containing molecules currently found in the lit-
EXAMPLES 
The following examples are intended to illustrate certain 
preferred embodiments of the invention and are not limiting 
US 10,173,968 B2 
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in nature. Those skilled in the art will recognize, or be able 
to ascertain, using no more than routine experimentation, 
numerous equivalents to the specific substances and proce-
dures described herein. 
Example 1 
To show the potential of various compounds disclosed 
herein, nine symmetrical bis(N-amidino)hydrazones (3A-B 
and 4A,C-H) and eight asymmetrical N-amidino-N'-aryl-
bishydrazones (7Aa-Ag and 8Aa) (Scheme 1, FIGS. A-B) 
were synthesized, and their antibacterial and antifungal 
activities were evaluated against panels of bacterial strains 
(four Gram-positive, six Gram-negative, and one mycobac-
terial) and seven Candida albicans strains. Because the 
development of resistance represents a crucial problem in 
antimicrobial drug development, the potential of resistance 
development by bacteria and fungi against these compounds 
was also established. Additionally, the production of reactive 
oxygen species (ROS) was measured in yeast cells of some 
of these compounds, and the compounds in vitro cytotox-
icity as well as the compounds minimal affinity, which is 
desired, for the hERG potassium chamiel was determined. 
The combination of testing new antimicrobial agents and 
early screening for resistance and toxicity represent an 
avenue most likely to produce pharmacophores of potential 
utility in disease treatment. 
16 
Design and Chemical Synthesis of Biscationic Com-
pounds with Chemically Non-Identical Termini 
Literature approaches for the synthesis of bicationic 
agents with two chemically non-identical termini typically 
involved the construction of the spacer as the ultimate step. 
For example, the coupling of an amidino-substituted naph-
tha! with a guanidine-substituted benzoic acid secured bis-
cationic esters with an amidinium group at one terminus and 
a guandinium group at the other. The synthetic approach that 
10 
is reported here differed from this strategy in that a stepwise, 
chemoselective modification ofbisaldehydes 1 or bisketones 
2 was used to arrive at biscationic systems with different 
cationic groups at each terminus. Condensations of one 
equivalent ofN-aminoguanidine hydrochloride with IA and 
2A led to the efficient production of mono substituted N-ami-
15 dinohydrazones SA and 6A, respectively (FIG. 18). The 
hydrochloride salts of these monocatioinic products were 
readily crystallized and thereby were isolated free from 
starting materials and suitable for the subsequent synthesis 
of the biscationic agents. For example, the subsequent 
20 treatment of SA and 6A with N-arylhydrazines furnished the 
desired, biscationic agents 7Aa-Ag and 8Aa, respectively, 
which we describe as N-amidino-N'-aryl-bishydrazones 
(FIG. 18). Cavallini described the monocationic N-amidi-
nohydrazones as antibacterial agents some years ago, but the 
25 range of organisms and MIC50 values were, in general, 
unimpressive. No effort was made by Cavallini to examine 
organisms which represent the most imminent threat to 
human health. Chemical Synthesis ofBiscationic Compounds with Two, 
Chemically Identical Termini 
To form the biscationic hydrazones of formula (III) with 30 
two N-amidino groups, the carbonyl groups in either bisal-
dehyde 1 or bisketone 2, which in some cases were in 
regiochemically distinct positions in the spacer (e.g., 18, 
28, 2H), were modified with N-aminoguanidine hydrochlo-
ride to obtain the biscationic products 3 and 4, respectively 35 
(FIG. lA). To form the biscationic hydrazones of formula 
(IV) with two N-aryl groups, the carbonyl groups in either 
bisaldehyde 1 or bisketone 2, which in some cases were in 
regiochemically distinct positions in the spacer (e.g., 18, 
28, 2H), were modified with N-arylhydrazines to obtain the 40 
biscationic products 9 and 10, respectively (FIG. 18). 
The antibacterial and antifungal properties of bis(N-ami-
dino )hydrazones 3 and 4 and N-amidino-N'-aryl-bishydra-
zones 7 and 8 were evaluated as discussed below. 
Antibacterial Activity 
To determine if bis(N-amidino)hydrazones and N-ami-
dino-N'-aryl-bishydrazones displayed antibacterial activity, 
compounds 3A-8Aa were evaluated against a panel of 
Gram-positive ( 4 strains), Gram-negative (6 strains), and 
one mycobacterial strain using the aminoglycoside amikacin 
(AMK), the ~-lactam ampicillin (AMP), and the fluoroqui-
nolone ofloxacin (OFX) as positive controls in a concentra-
tion range of 0.5-500 µM. The results are provided in Table 
1 below. 
TABLE 1 
MIC values in µg/mL and (µM)" for compounds 3A, B, 4A, C-H, 7Aa-Ag, and 8Aa 
against various bacterial strains. 
Gram-positive Gram-negative 
Cpd A B c D E F 
AMK 3.0-12.2 (3.9-15.6) 3.0 (3.9) 24.5 (31.3) 97.7 (125) 24.5 (31.3) 48.9 (62.5) 
AMP >92.8 (>250) 92.8 (250) 92.8 (250) 92.8 (250) >92.8 (>250) >92.8 (>250) 
OFX ,;0.2 (,;0.5) 0.4 (1.0) 0.4 (1.0) 2.8 (7.8) ,;0.2 (,;0.5) ,;0.2 (,;0.5) 
3A >198 (>500) 0.4 (1.0) 1.5 (3.9) 0.8 (2.0) >198 (>500) >198 (>500) 
3B >198 (>500) 0.4 (1.0) 1.5 (3.9) 1.5 (3.9) >198 (>500) >198 (>500) 
4A >212 (>500) >212 (>500) >212 (>500) >212 (>500) >212 (>500) 52.9 (125) 
4C >219 (>500) 1.7 (3.9) 1.7 (3.9) 0.9 (2.0) >219 (>500) >219 (>500) 
4D >226 (>500) 0.5 (1.0) 0.5-0.9 (1.0-2.0) 0.5 (1.0) >226 (>500) >226 (>500) 
4E 54.9 (125) 27.5 (62.5) 54.9 (125) 1.7 (3.9) 27.5 (62.5) 110 (250) 
4F 3.4 (7.8) <0.2 (<0.5) 0.4-0.9 (1.0-2.0) 0.4 (1.0) 218 (500) 218 (500) 
4G 86.8 (250) 86.8 (250) >173 (>500) 43.4 (125) 173 (500) >173 (>500) 
4H 86.8 (250) 86.8 (250) >173 (>500) 43.4 (125) >173 (>500) >173 (>500) 
7Aa >215 (>500) 0.4-0.9 (1.0-2.0) 0.9 (2.0) 0.9 (2.0) >215 (>500) >215 (>500) 
7Ab >235 (>500) 0.9 (2.0) 0.9 (2.0) 0.9 (2.0) >235 (>500) >235 (>500) 
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TABLE I-continued 
MIC values in µg/mL and (µM)" for compounds 3A, B, 4A, C-H, 7Aa-Ag, and 8Aa 
against various bacterial strains. 
7Ac >205 (>500) 0.8 (2.0) 3.2 (7.8) 1.6 (3.9) >205 (>500) >205 (>500) 
7Ad >214 (>500) 1.7 (3.9) 3.3 (7.8) 1.7 (3.9) >214 (>500) >214 (>500) 
7Ae 13.1 (31.3) 3.3 (7.8) 6.5 (15.6) 0.8-1.6 (2.0-3.9) 6.5-13.1 (15.6-31.3) 209 (500) 
7Af >214 (>500) 0.9-1.7 (2.0-3.9) 1.7 (3.9) 1.7 (3.9) >214 (>500) >214 (>500) 
7Ag >231 (>500) 3.6 (7.8) 3.6 (7.8) 3.6 (7.8) >231 (>500) >231 (>500) 
8Aa 26.6-53.3 (62.5-125) 26.6-53.3 (62.5-125) 53.3 (125) 1.7 (3.9) 26.6 (62.5) 213 (500) 
Gram-negative 
Cpd G H K 
AMK 24.5 (31.3) 24.5 (31.3) 48.9 (62.5) 3.0-6.1 (3.9-7.8) 12.2 (15.6) 
AMP >92.8 (>250) >92.8 (>250) >92.8 (>250) 92.8 (250) >92.8 (>250) 
OFX 1.4-2.8 (3.9-7.8) 5.6-11.3 (15.6-31.3) 1.4 (3.9) 5.6-11.3 (15.6-31.3) 5.6 (15.6) 
3A >198 (>500) >198 (>500) >198 (>500) >198 (>500) >198 (>500) 
3B >198 (>500) >198 (>500) >198 (>500) >198 (>500) 0.4 (1.0) 
4A 26.5 (62.5) 6.6 (15.6) 0.8 (2.0) >212 (>500) >212 (>500) 
4C >219 (>500) >219 (>500) >219 (>500) >219 (>500) 0.9 (2.0) 
4D >226 (>500) >226 (>500) >226 (>500) >226 (>500) 0.5 (1.0) 
4E 54.9 (125) 27.5 (62.5) 27.5 (62.5) 54.9 (125) 54.9-110 (125-250) 
4F 218 (500) 13.6-27.2 (31.3-62.5) 0.4-0.9 (1.0-2.0) 1.7 (3.9) 0.4 (1.0) 
4G >173 (>500) 173 (500) 86.8 (250) 86.8-173 (250-500) >173 (>500) 
4H >173 (>500) >173 (>500) 173 (500) 21.7-86.8 (62.5-250) 5.4 (15.6) 
7Aa >215 (>500) >215 (>500) >215 (>500) >215 (>500) 1.7 (3.9) 
7Ab >235 (>500) >235 (>500) >235 (>500) >235 (>500) 1.8 (3.9) 
7Ac >205 (>500) >205 (>500) >205 (>500) >205 (>500) 1.6 (3.9) 
7Ad >214 (>500) >214 (>500) >214 (>500) >214 (>500) 1.7 (3.9) 
7Ae 26.1-52.2 (62.5-125) 6.5-13.1 (15.6-31.3) 13.1-26.1 (31.3-62.5) 6.5 (15.6) 6.5-13.1 (15.6-31.3) 
7Af >214 (>500) >214 (>500) >214 (>500) >214 (>500) 0.9-1.7 (2.0-3.9) 
7Ag >231 (>500) >231 (>500) >231 (>500) >231 (>500) 1.8 (3.9) 
8Aa 213 (500) 26.6-53.3 (62.5-125) 213 (500) 26.3-53.3 (62.5-125) 213 (500) 
aThese antibacterial MIC values were originally determined in µMusing a range of 0.5 to 500 µM. These values are presented into parentheses. The values in µg/mL are presented 
for comparison with the antifungal MIC values which were originally determined in µg/mL. 
Gram-positive: A= B. subtilis 168, B = L. monocytogenes ATCC 19115, C = MR.SA, D = VRE. 
Gram-negative: E = A. baumannii ATCC 19606, F = E. cloacae ATCC 13047, G = E. coli MC1061, H = K. pneumoniae ATCC 27736, I= P. aerngi.nosa ATCC 27853, J = S. enterica 
ATCC 14028. 
Mycobacterial: K = M. smegmatis MC2-155. 
Control antibiotics: AMK = amikacin, AMP = ampicillin, OFX = ofloxacin. 
In general, the compounds displayed excellent (MIC 
values s0.5-7.8 µM), intermediate (15.6-31.3 µM), or low 
(62.5-;;,:500 µM) antibacterial activity against the bacterial 
strains tested. 
Overall, when analyzing the MIC data obtained against 
the Gram-positive bacterial strains (strains A-D), it was 
H; MIC=15.6 µM). Similarly, compound 4F also displayed 
excellent antibacterial activities against strain I (MIC=l.0-
40 2.0 µM) and S. enterica ATCC 14028 (strain J; MIC=3.9 
µM), as well as moderate to low activity against strain H 
(MIC=31.3-62.5 µM). Additionally, 7 Ae showed only mod-
noticed that most of the bis(N-amidino )hydrazones (3A,B, erate antibacterial activities against strain H (MIC= 15 .6-
4C,D, 4F) and N-amidino-N'-aryl-bishydrazones (7Aa-Ad, 45 31.3 µM), strain I (MIC=31.3-62.5 µM), and strain l 
and 7Af-Ag) showed excellent antibacterial activity against 
Listeria monocytogenes ATCC 19115 (strain B) (MIC <0.5-
(MIC=15.6 µM). Compounds 38, 4C-D, 4F, 7Aa-Ad, and 
7 .8 µM), methicillin-resistant Staphylococcus aureus 
(MRSA) (strain C) (MIC=l.0-7.8 µM), and vancomycin- 50 
resistant enterococcus (VRE) (strain D) (MIC=l.0-7.8 µM). 
All of the compounds displayed poor activity against Bacil-
7 Af-Ag exhibited excellent antibacterial activity (MIC val-
ues ranging from 1.0-3.9 µM) against M. smegmatis MC2-
155 (strain K), whereas compounds 411 and 7Ae showed 
only moderate activity (15.6-31.3 µM) and compounds 3A, 
4A, 4E, 4G, and 8Aa showed low activity (125-500 µM) 
!us subtilis 168 (strain A), with the exception of compound against this mycobacterial strain. It is noteworthy to mention 
4F, which displayed good activity (MIC=7.8 µM) against 55 that when compared to clinically relevant antibacterial 
this strain. Likewise, compound 7Ae exhibited excellent drugs, such as AMK (MIC=3.9-125 µM), AMP (MIC;;,:250 
antibacterial activity against L. monocytogenes ATCC 19115 
(strain B; MIC=7.8 µM) and VRE (strain D; MIC=2.0-3.9 
µM), and OFX (MICs0.5-31.3 µM), the compounds 
reported here showed either superior or comparable anti-
µM) but only moderate antibacterial activity against B. 60 bacterial activity against all bacterial strains tested relative 
subtilis 168 (strain A; MIC=31.3 µM) and MRSA (strain C; to these clinical agents. 
MIC=15.6 µM), respectively. Overall, compound 4F was Antifungal Activity 
The antifungal activity of the bis(N-amidino )hydrazones 
and N-amidino-N-aryl-bishydrazones was determined 
65 against a panel of seven Candida albicans strains in a 
concentration range of 0.5-31.3 µg/mL. The results are 
provided in Table 2 below. 
found to be the most active against Gram-positive bacteria. 
Compound 4A exhibited potent activity against P. aerugi-
nosa ATCC 27853 (strain I; MIC=2.0 µM) and moderate 
activity against Klebsiella pneumoniae ATCC 27736 (strain 
US 10,173,968 B2 
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TABLE 2 
MIC values in µg/mLa and (µM) for compounds 3A, B, 4A, C-H, 7Aa-Ag, and 8Aa against various C. albicans strains. 
C. albicans ATCC strain # 
Cpd 1003a 1237b 2310c 2876c 10231b 64124b 90819b 
AmB 3.9 (4.2) 3.9 (4.2) 3.9 (4.2) 3.9 (4.2) 3.9 (4.2) 2.0-3.9 (2.1-4.2) 2.0 (2.1) 
3A 7.8 (19.7) 15.6 (39.5) >31.3 (>79.2) 7.8 (19.7) 15.6 (39.5) >31.3 (>79.2) >31.3 (>79.2) 
3B 3.9 (9.9) 3.9 (9.9) 3.9 (9.9) 3.9 (9.9) 3.9 (9.9) 3.9 (9.9) 3.9 (9.9) 
4A 7.8 (18.4) >31.3 (>73.9) 3.9 (9.2) 2.0 (4.7) 2.0-3.9 (4.7-9.2) 2.0 (4.7) 3.9 (9.2) 
4C 7.8 (17.8) 7.8 (17.8) 7.8 (17.8) 3.9 (8.9) 7.8 (17.8) 7.8 (17.8) 7.8 (17.8) 
4D 15.6 (34.6) 15.6 (34.6) 31.3 (69.3) 3.9 (8.6) 7.8 (17.3) >31.3 (>69.3) 7.8 (17.3) 
4E 7.8 (17.8) 7.8 (17.8) 7.8 (17.8) 3.9 (8.9) 7.8 (17.8) 7.8 (17.8) 7.8 (17.8) 
4F 1.0 (2.3) 2.0 (4.6) 1.0 (2.3) 1.0 (2.3) 1.0-2.0 (2.3-4.6) 1.0 (2.3) 2.0 (4.6) 
4G >31.3 (>90.1) >31.3 (>90.1) >31.3 (>90.1) >31.3 (>90.1) >31.3 (>90.1) 31.3 (90.1) >31.3 (>90.1) 
4H >31.3 (>90.1) 31.3 (90.1 31.3 (90.1) 7.8 (22.5) >31.3 (>90.1) >31.3 (>90.1) >31.3 (>90.1) 
7Aa 2.0 (4.6) 3.9 (9.2) 2.0 (4.6) 2.0 (4.6) 2.0 (4.6) 3.9 (9.2) 2.0 (4.6) 
7Ab 2.0 (4.1) 3.9 (8.3) 3.9 (8.3) 3.9 (8.3) 2.0 (4.1) 3.9 (8.3) 3.9 (8.3) 
7Ac 2.0 (4.7) 7.8 (19.0) 3.9 (9.5) 3.9 (9.5) 7.8 (19.0) 31.3 (76.2) 3.9 (9.5) 
7Ad 3.9 (9.1) 15.6 (36.5) 3.9 (9.1) 7.8 (18.3) 7.8 (18.3) 15.6 (36.5) 7.8 (18.3) 
7Ae 7.8 (18.7) 15.6 (37.3) 15.6 (37.3) 15.6 (37.3) 15.6 (37.3) 31.3 (74.9) 15.6 (37.3) 
7Af 2.0 (4.5) 3.9 (9.1) 3.9 (9.1) 3.9 (9.1) 1.0 (2.3) 3.9 (9.1) 7.8 (18.2) 
7Ag 7.8 (16.8) 15.6 (33.8) 7.8 (16.8) 15.6 (33.8) 7.8 (16.8) 31.3 (67.8) 31.3 (67.8) 
8Aa 15.6 (34.3) 15.6 (34.3) 15.6 (34.3) 15.6 (34.3) 15.6 (34.3) 31.3 (68.7) 15.6 (34.3) 
aThese antifungal MIC values were originally determined in Dg/mL using a range of 0.5 to 31.3 µg/mL. The values in µM into parentheses are presented for 
comparison with the antibacterial MIC values which were originally determined in µM. 
bindicates strains that are resistant to FLC, ITC, and VOR according to ATCC. 
cindicates strains that are susceptible to FLC, ITC, and VOR according to ATCC. 
Control antifungal agent: ArnB = amphotericin B. 
The common antifungal agent amphotericin B (AmB) was 
used as a positive control. It was observed that compounds 
38, 4F, 7 Aa, 7 Ab, and 7 Af showed excellent antifungal 
activities against all fungal strains tested, with 4F showing 
superior (MIC=l.0-3.9 µg/mL) activity. Similarly, com-
pound 4A also displayed potent antifungal activities 
(MIC=2.0-3.9 µg/mL) against most strains except against C. 
albicans ATCC 1003 (MIC=7.8 µg/mL) and C. albicans 
ATCC 1237 (MIC=31.3 µg/mL). Compounds 7Ad, 7Ae, 
7Ag, and 8Aa showed only moderate fungal growth inhibi-
tion (MIC=7.8-15.6 µg/mL) against the majority of the 
fungal strains with the exception of C. albicans ATCC 
64124 (MIC=31.3 µg/mL for 7Ae, 7Ag, and 8Aa), C. 
albicans ATCC 90819 (MIC=31.3 µg/mL for 7Ag), C. 
albicans ATCC 1003 (MIC=3.9 µg/mL for 7Ad) and C. 
albicans ATCC 2310 (MIC=3.9 µg/mL for 7Ad). Com-
pounds 7 Ac also exhibited excellent growth inhibition 
against most of the fungal strains tested, except against C. 
albicans ATCC 10231 (moderate activity, MIC=7.8 µg/mL) 
and C. albicans ATCC 64124 (poor activity, MIC=31.3 
µg/mL). It is important to emphasize that most of the 
bis(N-amidino )hydrazones and N-amidino-N-aryl-bishydra-
zones displayed either superior or comparable antifungal 
activities against the majority of the fungal strains tested, 
when compared to the clinically relevant antifungal agents, 
AmB (MIC=2.0-3.9 µg/mL). 
SAR Analysis. 
Variations in SAR outcomes for compounds studied as 
antibacterial or as antifungal agents was expected given that 
bacteria are prokaryotic organisms and fungi are eukaryotic 
organisms. 
Based upon the antibacterial and antifungal results pre-
sented in Tables 1 and 2, it was determined that with respect 
to bis(N-amidino )hydrazones, linkers comprised of a single 
phenyl ring, regardless of its substitution pattern (para or 
meta, as in compounds 4G and 4H, respectively), displayed 
diminished but not non-existent antimicrobial activity as 
compared to the other linkers disclosed herein. Additionally, 
comparing the MIC value profiles of compounds 3A and 4A 
as well as 7 Aa and 8Aa, which only differ by the absence or 
presence of a methyl group on the carbons alpha to the 
phenyl rings indicated that the methyl group diminished 
30 antibacterial activity of these compounds relative to cases 
where the carbons alpha to the phenyl rings contained a 
hydrogen. However, the presence of the methyl group 
appeared beneficial in terms of antifungal activity. For 
example, compound 4A was overall a much better antifungal 
35 agent than compound 3A. Turning to the antibacterial MIC 
values for compounds 3A and 38, it was observed that they 
were about equivalent in all cases, except against strain K 
where the MIC value for compound 38 (MIC=l µM) was 
much lower than that for compound 3A (MIC>500 µM). 
40 From these data, it was deduced that the substitution patterns 
of the biphenyl linkers had minimal effects on antibacterial 
activity. However, the substitution patterns of the biphenyl 
linkers were found to have a substantial effect on antifungal 
activity. For example, compound 38 was a much better 
45 antifungal agent than compound 3A. 
With respect to the length of the flexible, linear, alkyl 
spacer between the two phenyl rings, comparing the MIC 
values of compounds 4A, 4C, and 4D, once again showed 
opposing trends in antibacterial and antifungal activities. In 
50 particular, increasing the length of the flexible alkyl linker 
between the two phenyl rings resulted in a decrease in 
antibacterial MIC values, whereas this same increase in the 
length of the linker resulted in an increase in antifungal MIC 
values. As to rigidity of the linker, by contrasting the MIC 
55 value profile of compound 4C containing a flexible linker to 
that of compound 4F containing a rigid linker, it was 
concluded that introducing rigidity in the linker was ben-
eficial for antimicrobial activity. In contrast to rigidity, a 
comparison of the MIC value profiles of compounds 4C and 
60 4E indicated that replacing the methylene bridging the two 
phenyl groups of the linker with an oxygen atom had no 
effect on antifungal activity, but was detrimental to antibac-
terial activity. 
Next, by comparing compounds 7 Aa-7 Ag, it was 
65 observed that the nature of the substituent in the ortho 
position of the mono-substituted aryl group of compounds 
7 Aa and 7 Ab did not affect antibacterial or antifungal 
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activity, whereas the nature of the substituent in the para 
position of the mono-substituted aryl group of compounds 
7 Ac-7 Ae had the opposing effects on antibacterial 
(CN>halogen) and antifungal (halogen>CN) activity. It was 
also observed that the o,p-difluorinated and o,p-dichlori- 5 
nated aryl moieties of compounds 7 Af and 7 Ag had similar 
overall antibacterial activity, but different antifungal activity, 
in which the o,p-difluorinated group possessed improved 
antifungal activity. Finally, with regard to the effect of 
substitution pattern of the aryl ring (ortho versus para- 10 
monosubstituted versus ortho,para-disubstituted) on antimi-
crobial activity, a comparison of the activity resulting from 
different chlorination patterns in compounds 7 Aa ( ortho ), 
7 Ad (para), and 7Ag (o,p-diCl), indicated that these changes 
had minimal effects on antibacterial activity but substantial 15 
effects on antifungal activity. The a-chlorinated N-amidino-
N-aryl-bishydrazone was superior to the p-chlorinated ana-
log, which in turn was much better than o,p-dichlorinated 
analog. 
Development of Bacterial and Fungal Resistance Studies 20 
The emergence of antibiotic resistance by microbes is an 
inevitable process; however, the frequency at which resis-
tance develops varies from one antibiotic to another. It is 
critical to assess the ability of new antimicrobials to evade, 
as long as possible, the development of bacterial and fungal 25 
resistance early in the development process. 
To establish if the bis(N-amidino )hydrazones and N-ami-
dino-N-aryl-bishydrazones evaded resistance in bacteria, a 
multi-step resistance selection experiment was performed 
with compounds 4D, 4F, and 7 Aa and with AMK as a 30 
reference drug against four bacterial strains (FIG. 2). L. 
monocytogenes ATCC 19115 (strain B), MRSA (strain C), 
VRE (strain D), and P. aeruginosa ATCC 27853 (strain I) 
were exposed to sub-inhibitory concentrations of com-
pounds 4D, 4F, 7 Aa, and AMK, and were sub-cultured for 35 
15 serial passages to determine if any increase in MIC values 
occurred for each compounds against the strains tested. L. 
monocytogenes ATCC 19115 (strain B), MRSA (strain C), 
VRE (strain D), and P. aeruginosa ATCC 27853 (strain I) 
did not develop resistance to compound 4F, as established by 40 
the fact that the relative MIC values increased only by 
one-fold after 15 serial passages. Likewise, strains Band D 
did not develop resistance to compound 7 Aa, but strains C 
and I developed resistance to this compound after twelve 
serial passages. In contrast, the rapid development of resis- 45 
tance to compound 4D was observed in strains C and D with 
a 16-fold increase in MIC values after fifteen serial passages. 
This resistance development against compound 4D was also 
observed in strains B and I, where increases in relative MIC 
values by 8- and 4-folds were observed after 15 passages. 50 
Interestingly, in strains D and I, resistance to the control 
antibiotic, AMK, was also observed after 3 and 5 passages, 
respectively, whereas in strains C and B, resistance devel-
oped after 12 and 15 passages, respectively. Overall, these 
results indicate that there is a low probability of emergence 55 
of resistance to the antifungal, biscationic compounds 4F 
and 7Aa. 
22 
Measurement of ROS Induction in Fungal Cells 
Various antifungal drugs, such as AmB and miconazole, 
as well as the antifungal agents of the present disclosure, 
were shown to mediate their inhibitory effect by inducing 
intracellular ROS production. Universally, eukaryotic cells 
produce basal amount of ROS in mitochondria as a byprod-
uct of cellular metabolism. In response, the cellular enzy-
matic antioxidants, including superoxide dismutase and glu-
tathione peroxidase, scavenge ROS in cells. However, 
overproduction of deleterious ROS perturbs the delicate, 
intracellular equilibrium between ROS production and scav-
enging, and results in cellular damage. 
To show the ability of compounds 4F and 7 Aa to alter 
ROS production in C. albicans ATCC 10231 (strain A), a 
fluorescent-based assay was performed using a 2',7'-dichlo-
rodihydrofluorescein diacetate (DCFH-DA) dye. It was 
found that treatment of C. albicans ATCC 10231 (strain A) 
with compounds 4F and 7Aa at their lx and 2xMIC values 
significantly increased intracellular ROS production in this 
fungal strain (FIG. 3). As expected, an H20 2 positive control 
(at 1 mM) also induced ROS production in yeast cell, 
whereas no ROS induction was observed with untreated 
yeast cells (negative control). 
Cytotoxicity 
Another important aspect to consider during the devel-
opment of antimicrobial agents is their potential toxicity 
towards manmialian cells. Having established the potent 
antimicrobial activities of the bis(N-amidino )hydrazones 
and N-amidino-N'-aryl-bishydrazones against bacteria and 
fungi, the toxicity profile of these compounds was deter-
mined against two mammalian cell lines (A549 and BEAS-
28; FIGS. 4A-B). The majority of the compounds showed 
dose-dependent toxicity with IC50 values of 1.95-3.9 µg/mL 
against these cell lines. Compounds 38, 7 Ac, 7 Ad, and 7 Af 
with antibacterial MIC values of <0.4-3.3 µg/mL, displayed 
good IC50 values of 7.8-15.6 µg/mL against both mamma-
lian cell lines. It is important to remember that compounds 
7 Ac and 7 Af also displayed strong antifungal MIC values. 
hERG Inhibition Assay 
The human Ether-a-go-go related gene (hERG) encodes a 
voltage-gated potassium channel that plays an essential role 
in regulating heart rhythm. Inhibition of the potassium 
channel coded by hERG disrupts the heart rhythm and may 
lead to death. Recently, clinically used drugs (e.g., terfen-
dadine and cisapride) were withdrawn from the market due 
to their interaction with hERG. Currently, the U.S. Food and 
Drug Administration (FDA) and the European Medicines 
Agency (EMA) require testing ofhERG affinity for potential 
novel drugs during the early stage of the drug development. 
A [3 H]-dofetilide competition binding assay using HEK-
293 cell membranes stably expressing hERG channel was 
performed to evaluate interaction of the most potent bis(N-
amidino )hydrazones and N-amidino-N'-aryl-bishydrazones 
with hERG (FIG. 5). Compounds exhibiting IC50 values of 
> 10 µMare considered to have desirable, low affinity for the 
hERG channel. Compounds displaying IC50 values in the 
range of 1-10 µM are considered moderate inhibitors, 
whereas compounds exhibiting IC50 values of <l µM are 
considered to have undesirable, high affinity for the hERG 
channel. The majority of the compounds of the present 
The potential development of drug resistance in C. albi-
cans ATCC 10231 to anti fungal compounds 7 Aa and 4 F was 
investigated. The results indicated that C. albicans ATCC 
10231 was unable to develop drug resistance to either 7 Aa 
or 4F, despite repeated treatments with sub-MIC drug con-
centrations. Only a slight 2-fold shift in relative MIC values 
was observed after 13 passages. These results also suggested 
the appearance of drug resistance by fungi to the antifungal 
compounds of the present disclosure is highly unlikely, a 
particularly desirable outcome. 
60 
disclosure displayed IC50 values within the acceptable range 
of 1-10 µM (FIG. 5) against the hERG channel. For 
example, the p-fluorophenyl and the 2,4-difluorophenyl 
groups in compounds 7 Ac and 7 Af displayed only moderate 
inhibition of the hERG channel with IC50 values of 
3.29±0.625 µMand 2.24±0.701 µM, respectively. Strikingly, 
65 both of these compounds displayed excellent antifungal 
activities and also exerted low mammalian cell toxicity. 
Similarly, compounds 4F and 7 Aa also displayed moderate 
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CAS: 109501-35-1. Yield: 86%; mp 340-342° C. 1H 
NMR (400 MHz, DMSO-d6) ll 7.84 (d, J=S.4 Hz, 4H, H-2), 
7.85 (br s, SH, CH NNHC(N!__U N!b +), 7.98 (d, J=S.4 
Hz, 4H, H-3), 8.24 (s, 2H, C!! NNHC(NH2) NH2 +), 11.8 
inhibition ofhERG channel with IC50 values of 1.12±0.317 
µM and 1.14±0.267 µM, respectively; however, they dis-
played some toxicity against mammalian cells. Therefore, it 
was concluded, once again, that compounds 7 Ac and 7 Af 
are the most promising N-amidino-N'-aryl-bishydrazones. 
Example 2 
Materials and Instrumentation. 
5 (br s, 2H, CH NNHC(NH2) NH2 +). 13C NMR (100 
MHz, DMSO-d6) Ii 127.0 (C-2), 128.2 (C-3), 133.0 (C-1), 
140.9 (C-4), 146.3 ~H NNHC(NH2) NH2+), 155.4 
(CH=NNH~(NH2)=NH2 +). HRMS (nEI) Calcd. for 
C16H21Cl2N8 [M+Ht: 323.1727. Found: 323.1727. Anal. 
1° Calcd. forC 16H20Cl2N8 : C, 48.62; H, 5.10; N, 28.35. Found: 
Chemicals were purchased from Sigma-Aldrich-Fluka 
(PO Box 14508 St. Louis, Mo., 63178, USA), Matrix, Inc. 
(131 Pontiac Business Center Dr., Elgin, S. C., 29045, 
USA), and Thermo-Scientific (7383 Empire Dr., Florence, 
Key., 41042, USA), or were synthesized according to lit-
erature procedures, unless otherwise noted. Solvents were 
used from commercial vendors without further purification 
unless otherwise noted. Nuclear magnetic resonance (NMR) 15 
spectra were determined in DMSO-d6 using an Agilent 400 
series NMR instrument. The DMSO center line was set as 
the reference at 2.5 ppm for 1H NMR spectra and at 39.51 
ppm for 13C NMR spectra. LRMS electron-impact (EI) 
ionization mass spectra were recorded at 70 eV on a Ther- 20 
moFinnigan PolarisQ (ion trap mass spectrometer). Samples 
were introduced via a heatable direct probe inlet. High-
resolution electron impact (EI) ionization mass spectra were 
recorded at 25 e Von a JEOL JMS-700T MStation (magnetic 
sector instrument) at a resolution of greater than 10,000. 25 
Samples were introduced via heatable direct probe inlet. 
MALDI mass spectra were obtained on a Bruker Utraflex-
streme time-of-flight mass spectrometer (Billerica, Mass.), 
using DHB (2,5-dihydroxybenzoic acid) matrix. Purity of 
compounds was >95% as established by combustion analy-
30 
ses. In the case of compounds that resisted crystallization or 
were too valuable to sacrifice to combustion, purity was 
established by a combination of high-resolution mass spec-
tra and 13C NMR data. Elemental analyses were determined 
by Atlantic Microlabs, Inc. (6180 Atlantic Blvd# M, Nor-
cross, Ga., 30071, USA). Compounds were chromato- 35 
graphed on preparative layer Merck silica gel F254 or 
colunms using MP Silica 63-200, 60 A, MP EcoChrom 
(Eschwege, Germany). Organic solutions were dried over 
anhydrous MgS04 unless otherwise noted. 
Experimental Procedures and Characterization of Com- 40 
pounds 3A-8Aa: 
General Procedure for the Synthesis of Ary! Bis[N-
(Guanidino )!mines] 3A-4H. 
To a solution of aminoguanidine hydrochloride (2 mmol, 
2 eq) in 3 mL of absolute EtOH at 78° C. was added 1 mmol 45 
(1 eq) ofbisaldehyde 1 (R=H) or bisketone 2 (R=CH3) and 
10 µL of concentrated HCI. The mixture was heated for 2 h 
and cooled to 0° C. The resulting white solid was filtered and 
washed with 2 mL of cold EtOH to afford aryl N-(guanidino) 
imines 3A-B and 4A,C-H as dihydrochloride salts. 
Characterization of Compounds 3A-B and 4A,C-H: 
(2E,2'E)-2,2'-([1, 1 '-Biphenyl]-4,4'-diylbis(methany-
lylidene ))bis(hydrazine-1-carboximidamide) dihy-
drochloride1 (3A) 
•HCl 
50 
55 
H 
~N,...N~NH 
I 60 
NH2 
C, 48.72; H, 5.01; N, 28.20. 
(2E,2'E)-2,2'-([ 1, 1 '-Biphenyl]-3,4'-diylbis(methany-
lylidene) )bis(hydrazine-1-carboximidamide) dihy-
drochloride (38) 
5' 
2' 
NH2 
9 N....._N_,,,l.NH 
H 
•HCl 
•HCl 
Yield: 73%; mp 368-370° C. 1H NMR (400 MHz, 
DMSO-d6) ll 7.53 (t, J=S.O Hz, lH, H-5'), 7.78-7.85 (m, 4H, 
H-2, H-4', H-6 and H-6'), 7.96 (d, J=S.4 Hz, 2H, H-3 and 
H-5), 7.2-8.5 (br s, SH, CH NNHC(NH2) N!b +), 8.21 (s, 
lH, CH NNHC(NH2) NH2 +), 8.22 (br s, lH, H-2'), 8.23 
(s, lH, CH NNHC(NH2)=NH2+), 12.1 (br s, 2H, 
CH NNHC(NH2) NH2 +). 13C NMR (100 MHz, DMSO-
d6) ll 125.6 (C-2'), 127.1 (C-2 and C-6), 127.2 (C-6'), 128.2 
(C-3 andC-5), 128.8 (C-4'), 129.4 (C-5'), 132.9 (C-1'), 134.2 
(C-1), 139.8 (C-3'), 141.2 (C-4), 146.4 
~H=NNHC(NH2)=NH2+), 146.6 
~H=NNHC(NH2)=NH2+), 155.4 (CH NNH 
~(NH2)=NH2+), 155.5 (CH=NNH~(NH2)=NH2+). 
HRMS (nEI) Calcd. for C12H19N8 [M+Ht: 275.1727. 
Found: 275.1726. 
(2E,2'E)-2,2'-([1, 1 '-Biphenyl]-4,4'-diylbis( ethan-1-
yl-1-ylidene) )bis(hydrazine-1-carboximidamide) 
dihydrochloride2 ( 4A) 
NH2 
HNAN,...N'-"':::: 
H 
•HCl 
CAS: 5961-64-8. Yield: 80%; mp >380° C. 1HNMR (400 
MHz, DMSO-d6) Ii 2.4 (s, 6H, C(C 
H3 ) NNHC(NH2) NH2+), 7.78 (d, J=S.4 Hz, 4H, H-2), 
7.9 (br s, SH, C(CH3)=NNHC(N!b)=NH2+), 8.07 (d, 
65 J=S.4 Hz, 4H, H-3), 11.4 (br s, 2H, C(CH3) NN 
HCCNH2)=NH2+). 13C NMR (100 MHz, DMSO-d6) ll 14.7 
(C~H3) NNHC(NH2) NH2 +), 126.5 (C-2), 127.4 (C-3), 
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136.2 (C-1), 140.3 (C-4), 151.2 
~(CH3) NNHC(NH2) NH2+), 156.1 (C(CH3) NNH 
QNH2) NH2 +). HRMS (nEI) Calcd. for C18H23N8 
[M+Ht: 351.2040. Found: 351.2040. Anal. Calcd. for 
C18H24Cl2N8: C, 51.07; H, 5.71; N, 26.47. Found: C, 51.15; 5 
H, 5.68; N, 26.37. 
(2E,2'E)-2,2'-( (methylenebis( 4, 1-phenylene) )bis 
( ethan- l-yl-1-ylidene ))bis(hydrazine-1-carboximid-
amide) dihydrochloride ( 4C) 
26 
(2E,2'E)-2,2'-((0xybis( 4, 1-phenylene ))bis( ethan-l-
yl-1-ylidene ))bis(hydrazine-1 carboximidamide ), 
dihydrochloride4 ( 4E) 
CAS: 17027-93-9. Yield: 73%; mp 340-342° C. 1H NMR 
(400 MHz, DMSO-d6) Ii 2.35 (s, 6H, C(C 
NH2 
'7'N'NANH 
H 
•HCl 
15 H_3) NNHC(NH2) NH2-), 7.08 (d, J=S.4 Hz, 4H, H-2), 
7.74 (br s, SH, C(CH3) NNHC(NH_2) NH_2+), 8.02 (d, 
J=S.4 Hz, 4H, H-3), 11.0 (br s, 2H, C(CH3) NN 
H_C(NH2)=NH2+). 
13C NMR (100 MHz, DMSO-d6) ll 14.6 
(C(CH_3) NNHC(NH2) NH2 +), 118.3 (C-2), 128.8 (C-3), 
Yield: 91%; mp 342-344° C. 1H NMR (400 MHz, 
DMSO-d6) Ii 2.32 (s, 6H, C(C!_h)=NNHC(NH2)=NH2 +), 
4.02 (s, 2H, ArCH_2Ar), 7.28 (d, J=S.4 Hz, 4H, H-2), 7.81 (br 
20 132.4 (C-4), 150.9 ~(CH3) NNHC(NH2) NH2+), 156 
(C-1), 157.5 (C(CH3)=NNH~(NH2)=NH2+). HRMS 
(nEI) Calcd. for C18H23Ng0 [M+Ht: 367.1989. Found: 
367.1987. Anal. Calcd. for C18H24Cl2N80: C, 49.21; H, 
5.51; N, 25.51. Found: C, 49.12; H, 5.53; N, 25.43. 
s, SH, C(CH3) NNHC(N~)'N~ +), 7.87 (d, J=S.4 Hz, 4H, 25 
H-3), 11.3 (br s, 2H, C(CH3) NNH_C(NH2) NH2 +). 13C 
NMR (100 MHz, DMSO-d6) Ii 14.6 (C~H3)= 
NNHC(NH2) NH2 +), 40.4 (~H2Ar), 126.9 (C-2), 128.6 
(C-3), 134.8 (C-1), 142.8 (C-4), 151.5 ~(CH3)= 30 NNHC(NH2) NH2+), 156 (C(CH3) NNH 
QNH2) NH2 +). HRMS (nEI) Calcd. for C19H25N8 
[M+Ht: 365.2197. Found: 365.2197. Anal. Calcd. for 
C19H26Cl2N8: C, 52.18; H, 5.99; N, 25.62. Found: C, 51.85; 
H, 5.95; N, 25.31. 35 
(2E,2'E)-2,2'-((9H-Fluorene-2, 7-diyl)bis( ethan-1-yl-
l-ylidene ))bis(hydrazine-1-carboximidamide) dihy-
drochloride ( 4F) 
(2E,2'E)-2,2'-( (Ethane-1,2-diylbis( 4, 1-phenylene )) 
bis( ethan- l-yl-1-ylidene ))bis(hydrazine-1-carboxi-
midamide) dihydrochloride3 (4D) 
CAS: 63956-03-6, NCI 304392. Yield: 96%; mp >380° C. 
40 
1H NMR (400 MHz, DMSO-d6) Ii 2.42 (s, 6H, C(CH3) 
NNHC(NH2) NH2+), 4.01 (s, 2H, H-7), 7.88 (br s, SH, 
C(CH3)=NNHC(NH2)=NH2+), 8.01 (d, J=S.4 Hz, 2H, 
H-4), 8.03 (d, J=S.4 Hz, 2H, H-3), 8.24 (s, 2H, H-1), 11.33 
(br s, 2H, C(CH3)=NNHC(NH2)=NH2 +). 
13C NMR (100 
MHz, DMSO-d6) ll 14.8 (C~H3)=NNHC(NH2)=NH2+), 
36.5 (C-9), 120.3 (C-4), 123.6 (C-1), 125.9 (C-3), 135.8 
•HCl 
(C-6), 141.9 (C-5), 143.8 (C-2), 151.8 (C(CH3) NNHC 
(NH2)=NH2+), 156.1 (C(CH3)=NNHC(NH2)=NH2+). 
HRMS (nEI) Calcd. for C19H23N8 [M+Ht: 363.2040. 
•HCl 
50 
Found: 363.2039. Anal. Calcd. for C19H24Cl2N8.1hH20: C, 
51.36; H, 5.67; N, 25.22. Found: C, 51.19; H, 5.59; N, 25.06. 
CAS: 5265-92-9. Yield: 66%; mp >380° C. 1H NMR (400 
MHz, DMSO-d6) Ii 2.33 (s, 6H, C(C 
55 
!b)=NNHC(NH2) NH2 +), 2.94 (s, 4H, Ar(C~)2Ar), 
7.25 (d, J=S.4 Hz, 4H, H-2); 7.81 (br s, SH, C(CH3) 
=NNHC(NH2) NH2+), 7.86 (d, J=S.4 Hz, 4H, H-3), 11.25 
(br s, 2H, C(CH3)=NNH_C(NH2)=NH2 +). 13C NMR (100 
MHz, DMSO-d6) Ii 14.6 (C~H3)=NNHC(NH2)=NH2+), 60 
36.3 (Ar~H2)2Ar), 126.7 (C-2), 128.4 (C-3), 134.5 (C-1), 
143.1 (C-4), 151.6 ~(CH3) NNHC(NH2) NH2+), 156.0 
(C(CH3) NNHQNH2) NH2 +). HRMS (nEI) Calcd. for 
C20H27N8 [M+Ht: 379.2352. Found: 379.2352. Anal. 65 
Calcd. forC20H28Cl2N8: C, 53.22; H, 6.25; N, 24.82. Found: 
C, 52.93; H, 6.09; N. 25.05. 
(2E,2'E)-2,2'-(1,4-Phenylenebis( ethan-1-yl-1-
ylidene) )bis(hydrazine-1-carboximidamide) dihydro-
chloride4 ( 4G) 
•HCl 
•HCl 
H 
~N/NYNH 
NH2 
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CAS: 2299-94-7. Yield: 97%; mp>380° C. 1H NMR (400 
MHz, DMSO-d6) Ii 2.38 (s, 6H, C(C 
!b)=NNHC(NH2+) NH2+), 7.87 (br s, SH, C(CH3) 
=NNHC(NH_2) N~ -), 7.99 (s, 4H, H-2, H-3), 11.3 (br s, 
2H, C(CH3) NNH_C(NH2) NH2 +). 13C NMR (100 MHz, 5 
DMSO-d6 ) Ii 14.7 (ArC( NNHR)~H3), 126.6 (C-2, C-3, 
C-5, and C-6), 137.8 (C-1 and C-4), 151.1 (Ar 
Q NNHR)CH3), 156.067 (NH~(NH2)=NH2+). HRMS 
(nEI) Calcd. for C12H19N8 [M+Ht: 275.1727. Found: 
275.1726. Anal. Calcd. for C12H20Cl2N8 .1/2H20: C, 40.46; 
10 
H, 5.94; N, 31.45. Found: C, 40.68; H, 6.10; N, 31.26. 
(2E,2'E)-2,2'-(1,3-Phenylenebis( ethan-1-yl-1-
ylidene ))bis(hydrazine-1-carboximidamide) dihydro- 15 
chloride6 (411) 
28 
Characterization of Compounds 7 Aa-Ag and 8Aa: 
E)-2-(( 4'-((E and Z)-(2-(2-Chlorophenyl)hydrazono) 
methyl)-[ 1, 1 '-biphenyl]-4-yl)methylene )hydrazine-1-
carboximidamide monohydrochloride (7 Aa) 
3' H 6" :::::,_,...ND,,~ 
N "°" 5" 
2'1 #4" 
Cl 
3
,, 
Yield: 70%; mp 328-330° C. 1H NMR, (400 MHz, 
DMSO-d6 ) ll 6.81 (dt, 1=8.4 and 1.6 Hz, lH, H-4"), 7.28 (dt, 
20 1=7.6 and 1.2 Hz, lH, H-5"), 7.34 (dd, 1=8.0 and 1.6 Hz, 1, 
H-3"), 7.6 (dd, 1=8.4 and 1.2 Hz, lH, H-6"), 7.75-7.80 (m, 
4H, H-2 and H-2'), 7.80 and 7.84 (two d, 1=8.4 Hz, lH, 
45:55 ratio ofsyn:anti H-3'), 7.97 and 7.98 (two d, 1=8.4 Hz, 
lH, 45:55 ratio of syn:anti H-3), 8.23 and 8.234 (twos, lH, 
CAS: 87533-31-1. Yield: 86%; mp 330-332° C. 1H NMR 
(400 MHz, DMSO-d6 ) Ii 2.42 (s, 6H, C(C 
!b)=NNHC(NH2) NH2 +), 7.47 (t, 1=8.0 Hz, lH, H-5), 
7.87 (br s, SH, C(CH3)=NNHC(N~)=NH_2+), 8.03 (dd, 
1=8.0 and 2.0 Hz, 2H, H-4 and H-6), 8.26 (t, 1=2.0 Hz, lH, 
H-2), 11.34 (br s, 2H, C(CH3)=NNHCCNH2) NH2 +). 13C 
NMR (100 MHz, DMSO-d6 ) Ii 15.0 (CH3), 124.8 (C-5), 
128.0 (C-4 and C-6), 128.4 (C-2), 137.1 (C-1 and C-3), 
151.7 QCH3)=NNHC(NH2)=NH2+), 156.2 (C(CH3) 
=NNH~(NH2) NH2 +). HRMS (nEI) Calcd. for C12H19N8 
[M+Ht: 257.1727. Found: 275.1726. Anal. Calcd. for 
C12H20Cl2N8 : C, 41.51; H, 5.81; N, 32.27. Found: C, 41.27; 
H, 5.71; N, 32.13. 
25 
45:55 ratio of syn:anti ~H NNHAr), 8.34 (s, lH, 
~H NNHC(NH2) NH2 +), 9.98 and 10 (two br s, lH, 
55:45 ratio of anti:syn CH=NNH_Ar), 12.03 and 12.08 (two 
br s, lH, 45:55 ratio of syn:anti CH NN 
H_C(NH2)=NH2 +). 
13C NMR (100 MHz, DMSO-d6) Ii 
114.1 (C-2"), 116.23 and 116.3 (anti:syn C-6"), 119.7 and 
30 119.8 (anti:syn C-4"), 126.6 and 126.8 (anti:syn C-2'), 126.6 
and 126.8 (anti:syn C-3'), 126.7 and 126.8 (syn:anti C-2), 
127 and 127.1 (anti:syn C-3), 128.1 and 128.3 (syn:anti 
C-3'), 129.4 (C-3"), 132.7 and 133 (syn:anti C-1 '), 134.7 and 
135.1 (anti:syn C-1), 139.1 and 139.4 (anti:syn C-4'), 139.8 
35 and 139.9 (syn:anti C-4'), 140.9 and 141.3 (syn:anti C-1'), 
141.33 and 141.3 ( syn:anti ~H=NNHC(NH2)=NH2 +), 
146.3 and 146.4 (anti:syn ~H=NNHAr), 155.38 and 155.4 
(syn:anti CH=NNHQNH2) NH2 +). HRMS (nEI) Calcd. 
forC21 H20N6Cl [M+Ht: 391.1432. Found: 391.1431.Anal. 
40 Calcd. forC21H20C12N6 .1hH20: C, 57.81; H, 4.85; N, 19.26. 
General Procedure for the Synthesis of Ary! N-(Guani-
dino )!mines N'-Arylhydrazones 7 Aa-Ag and 8Aa. 
To 40.5 mmol (3 eq) of a bis(aldehyde) IA (R=H) or 
bis(ketone) 2A (R=CH3) in 20 mL of absolute EtOH at 78° 
45 
C. was added dropwise a solution of 1.5 g (13.5 mmol, 1 eq) 
of aminoguanidine hydrochloride in 80 mL of 1:15/H20: 
EtOH. To this solution was added 2 mL of concentrated HCI, 
and the mixture was heated for an additional 12 h. The 
50 
mixture was concentrated under vacuum to afford a solid. 
The solid was heated with ca. 10 mL of EtOAc to dissolve 
any unreacted dicarbonyl compound, as confirmed by TLC 
of the undissolved solid using 1:50/MeOH:CH2Cl2. After 
decanting the EtOAc solution, the remaining white precipi- 55 
tate consisted of the mono substituted N-(guanidino )imine 
SA and 6A that was used directly in the next step. To 113 mg 
(0.5 mmol, 1 eq) of SA or 6A suspended in 2 mL of absolute 
EtOH at 78° C. was added 0.5 mmol (1 eq) of an aryl 
hydrazine followed by 0.02 mL of concentrated HCI. A clear 60 
solution was produced by the addition of acid, and within 
15-30 min, a precipitate was formed. The mixture was 
heated at 78° C. for 24 h, and the precipitate was collected 
by filtration of the hot mixture. The precipitate was washed 
cold absolute EtOH to yield >95% of pure unsymmetrical 65 
aryl N-(guanidino)imines N'-arylhydrazones 7Aa-Ag and 
8Aa. 
Found: C, 58.46; H, 4.69; N, 19.27. 
(E)-2-(( 4'-((E and Z)-(2-(2-Bromophenyl)hydra-
zono )methyl)-[!, 1 '-biphenyl]-4-yl)methylene )hydra-
zine-1-carboximidamide monohydrochloride (7 Ab) 
3' H 6" :::::,_,...ND,,~ 
N "-<: 5" 
I A4" 
B 2" ,;,, 
r 3" 
Yield: 64%; mp >380° C. 1 H NMR ( 400 MHz, DMSO-d6 ) 
Ii 6.75 (dt, 1=8.4 and 1.6 Hz, lH, H-4"), 7.32 (dt, 1=7.6 and 
1.2 Hz, lH, H-5"), 7.5 (dd, 1=8.0 and 1.6 Hz, lH, H-3"), 7.58 
(dd, 1=8.4 and 1.2 Hz, lH, H-6"), 7.75-7.85 (m, 6H, H-2, 
H-2', and H-3'), 7.80 (br s, 4H, CH=NNHC(N~)=NH2+), 
7.97 and 7.98 (two d, 1=8.4 Hz, lH, 45:55 ratio of syn:anti 
H-3), 8.227 and 8.232 (two s, lH, 45:55 ratio of syn:anti C 
H NNHAr), 8.364 (s, lH, CH=NNH_C(NH2)=NH2+), 
9.74 and 9.75 (two br s, lH, 45:55 ratio ofanti:syn CH NN 
H_Ar), 11.97 and 12.03 (two br s, lH, 45:55 ratio of syn:anti 
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CH NNHC(NH2) NH2 +). 
13C NMR (100 MHz, DMSO-
d6) Ii 106.1 and 106.2 (anti:syn C-2"), 114.6 (C-6"), 120.4 
and 120.5 (anti:syn C-4"), 126.66 and 126 72 (anti:syn C-2), 
126.7 and 127 (anti:syn C-3'), 126.8 and 127.1 (anti:syn 
C-2'), 128.3 (C-3), 128.6 (C-5"), 132.6 (C-1'), 132.6 and 133 5 
(anti:syn C-3"), 134.7 and 135.1 (anti:syn C-1), 139.1 and 
139.4 (anti:syn C-4"), 140 and 140.1 (syn:anti C-4), 141 and 
141.3 (anti:syn C-1"), 142.34 and 142.38 (syn:anti 
~H NNHC(NH2) NH2 +), 146.4 and 146.5 (syn:anti 
~H NNHAr), 155.34 and 155.36 (syn:anti CH NNH 10 
QNH2) NH2 +). HRMS (nEI) Calcd. for C21H19BrN6 
[M+Ht: 435.0927. Found: 435.0928. Anal. Calcd. for 
C21H20BrClN6: C, 53.46; H, 4.27; N, 17.81. Found: C, 
12.05 (br s, lH, CH=NNHCCNH2)=NH2+). 13C NMR 
(100 MHz, DMSO-d6) Ii 113.5 (C-2"), 122.0 (C-4"), 126.3 
(C-2'), 126.7 (C-2), 127 (C-3'), 128.2 (C-3), 128.9 (C-3"), 
133 (C-1'), 134.8 (C-1), 136.8 ~H NNHAr), 139.0 (C-4'), 
141.0 (C-4), 144.2 (C-1"), 146.4 ~H= 
NNHC(NH2)=NH2-), 155.4 (CH=NNH~(NH2)=NH2+). 
HRMS (nEI) Calcd. for C21 H20ClN6 [M+Ht: 391.1432. 
Found: 391.1431. Anal. Calcd. for C21 H20Cl2N6: C, 59.02; 
H, 4.72; N, 19.67. Found: C, 59.22, H, 4.75; N, 19.46. 
(E)-2-(( 4'-((E and Z)-(2-( 4-Cyanophenyl)hydrazono) 
methyl)-[ 1, 1 '-biphenyl]-4-yl)methylene )hydrazine-1-
carboximidamide monohydrochloride (7 Ae) 
53.10; H, 4.29; N, 17.19. 
(E)-2-(( 4'-((E)-(2-( 4-Fluorophenyl)hydrazono) 
methy 1)-[ 1, 1 '-biphenyl ]-4-y l)methy lene )hydrazine-1-
carboximidamide monohydrochloride (7 Ac) 
3' H 2" 
N "'3" 
15 
20 
NH2 
HNAN,..N~ 4 
H 
•HCl 
::::,,.,..Nu,,~ 
I 
#4" F 25 
Yield: 88%; mp >380° C. 1HNMR(400MHz, DMSO-d6) 
ll 7.07 (d, J=7.6 Hz, 2H, H-2"), 7.09 (d, J=7.6 Hz, 2H, H-3"), 
7.73 (s, 4H, H-2 and H-2'), 7.82 (br s, 4H, CH=NNHC(N 
~)=N!:!2+), 7.84 (d, J=8.4 Hz, 2H, H-3'), 7.91 (s, lH, C 
!:! NNHAr), 7.98 (d, J=8.4 Hz, 2H, H-3), 8.24 (s, lH, C 
!:! NNHC(NH2) NH2+), 10.5 (br s, lH, CH=NN!:!Ar), 
12.08 (br s, lH, CH=NNHCCNH2)=NH2+). 13C NMR 
(100 MHz, DMSO-d6) Ii 113 (C-2"), 115.6 (C-3"), 126.2 
(C-2'), 126.6 (C-2), 127.0 (C-3'), 128.2 (C-3), 133.0 (C-1'), 
135 (C-1), 136 ~H NNHAr), 138.8 (C-4'), 140.9 (C-4), 
141.9 (C-1"), 146.3 ~H NNHC(NH2)=NH2+), 155.4 
(CH NNH~(NH2)=NH2+), 156.4 (C-4"). HRMS (nEI) 
Calcd. forC21H20FN6 [M+Ht: 375.1728. Found: 375.1728. 
Anal. Calcd. for C21H20ClFN6: C, 61.39; H, 4.94; N, 20.18. 
Found: C, 61.48; H, 4.94; N, 20.18. 
(E)-2-(( 4'-((E)-(2-( 4-Chlorophenyl)hydrazono) 
methy 1)-[ 1, 1 '-biphenyl ]-4-y l)methy lene )hydrazine-1-
carboximidamide monohydrochloride (7 Ad) 
Yield: 80%; mp >380° C. 1HNMR(400MHz, DMSO-d6) 
Yield: 33%; mp 308-310° C. 1H NMR (400 MHz, 
DMSO-d6) Ii 7.19 (d, J=8.4 Hz, 2H, H-2"), 7.64 (d, J=8.4 
Hz, 2H, H-3"), 7.4-7.8 (br s, 4H, CH NNHC(NH.2) N 
30 
!:!2+), 7.76-7.85 (m, 6H, H-2, H-2', and H-3'); 7.973 and 
7.981 (two d, J=8.0 Hz, 2H, 58:42 ratio of anti:syn H-3), 
8.036 and 8.041 (two s, lH, 58:42 ratio of anti:syn C 
H NNHAr), 8.220 and 8.226 (two s, lH, 58:42 ratio of 
anti:syn CH NNHC(NH2) NH2 +), 11.12 and 11.16 (two 
35 br s, lH, 58:42 ratio of anti:syn CH NNHAr), 11.87 and 
11.93 (two br s, lH, 58:42 ratio of anti:syn CH NN 
HCCNH2)=NH2 +). 13C NMR (100 MHz, DMSO-d6) Ii 
99.35 (syn Ar~N), 99.40 (anti Ar~N), 112.2 (C-2"), 
120.1 (C-4"), 126.74 (anti C-2), 126.82 (syn C-2'), 126.819 
40 (anti C-3'), 126.98 (syn C-3'), 132.69 (anti C-1 '), 132.98 (syn 
C-1'), 133.7 (C-3"), 134.4 (syn C-1), 134.7 (anti C-1), 139.3 
and 139.5 (syn:anti ~H NNHAr), 139.57 and 139.60 (anti: 
syn C-4'), 140.96 and 141.2 (syn:anti C-4), 146.4 and 146.5 
(syn:anti ~H=NNHC(NH2)=NH2+), 148.54 (anti C-1"), 
45 148.55 (syn C-1 "), 155.26 and 155.3 (anti:syn CH NNH 
~(NH2)=NH2 +). HRMS (nEI) Calcd. for C22H19ClN7 
[M+Ht: 382.1775. Found: 382.1771. Anal. Calcd. for 
C22H20ClN7 : C, 63.23; H, 4.82; N, 23.46. Found: C, 63.17; 
50 
55 
60 
H, 4.80; N, 23.16. 
(E)-2-(( 4'-((E)-(2-(2,4-Difluorophenyl)hydrazono) 
methyl)-[1,1 '-biphenyl]-4-yl)methylene) hydrazine-
1-carboximidamide, monohydrochloride (7 Af) 
ll 7.10 (d, J=8.4 Hz, 2H, H-2"), 7.26 (d, J=8.4 Hz, 2H, H-3"), 
7.74 (brs, 4H, CH=NNHC(N~)=N!:!2+), 7.74 (s, 4H, H-2 
and H-2'), 7.84 (d, J=8.4 Hz, 2H, H-3'), 7.93 (s, lH, C 65 
!:! NNHAr), 7.98 (d, J=8.4 Hz, 2H, H-3), 8.23 (s, lH, C 
NH2 
HNAN,..N~ 
H 
•HCl 
Yield: 84%; mp >380° C. 1 H NMR ( 400 MHz, DMSO-d6) 
Ii 7.02 (dt, J=9.6 and 2.8 Hz, lH, (H-3"), 7.22 (ddd, J=ll.6, !:! NNHC(NH2) NH2+), 10.65 (br s, lH, CH=NN!:!Ar), 
US 10,173,968 B2 
31 32 
Yield: 95%; mp >380° C. 1HNMR (400MHz, DMSO-d6) 
Ii 2.36 (s, 3H, C(CH_3 ) N-NH-Ar), 2.37 (s, 3H, C(C 
H3 ) N-NH----C(NH2) NH2 +), 6.87 ( dt, J=8.0 and 1.2 
Hz, lH, H-4"), 7.32 (dt, J=8.0 and 1.2 Hz, lH, H-5"), 7.39 
(dd, J=8.0 and 1.2 Hz, lH, H-6"), 7.65 (dd, J=8.0 and 1.2 Hz, 
lH, H-3"), 7.20-8.20 (br s, 4H, C(CH3 )=N-NH-C(N 
H2) N~ +), 7.78 (d, J=8.4 Hz, 2H, H-2' and H-6'), 7.79 (d, 
J=8.4 Hz, 2H, H-3' and 5'), 7.95 (d, J=8.4 Hz, 2H, H-2 and 
H-6), 8.08 (d, '=8.4 Hz, 2H, H-3 and H-5), 8.28 (s, lH, 
8.4, and 2.8 Hz, lH, H-6"), 7.53 (dd, J=9.6 and 6.0 Hz, lH, 
H-5"), 7.74 (br s, 4H, CH NNHC(NH_2) NH_2+), 7.75 (s, 
4H, H-2 and H-2'), 7.85 (d, J=8.4 Hz, 2H, H-3') 7.98 (d, 
J=8.4 Hz, 2H, H-3), 8.15 (s, lH, C 
H=NNHC(NH2) NH2 +), 8.22 (s, lH, CH_ NNHAr), 5 
10.29 (br s, lH, CH=NNH_Ar), 11.8 (br s, lH, CH NN 
HC(NH2) NH2 -). 
13C NMR (100 MHz, DMSO-d6) Ii 
104.0 (C-6"), 111.5 (C-3"), 114.1 (C-5"), 126.5 (C-2'), 126.7 
(C-2), 126.1 (C-3'), 128.3 (C-3), 130.3 (C-1"), 133.0 (C-1'), 
134.8 (C-1), 139.0 (C-4'), 139.2 (C-4), 141.0 
~H NNHAr), 146.3 ~H NNHC(NH2) NH2+), 153.1 
(C-4"), 155.6 (C-2"), 155.4 (CH NNH~(NH2)=NH2+). 
HRMS (nEI) Calcd. for C21 H19N6F2 [M+Ht: 393.1634. 
Found: 393.1631.Anal. Calcd. forC21H19N6ClF2: C, 58.81; 
10 C(CH3 )=N-NH_-Ar), 10.83 (br s, lH, C(CH3)=N-N 
H----C(NH2) NH2 +). 
13C NMR (100 MHz, DMSO-d6) Ii 
12.5 C~H3 )=N-NH-Ar), 13.8 (C( 
CH3 ) N-NH----C(NH2) NH2+), 114.7 (C-2"), 117.5 
(C-6"), 120.3 (C-4"), 126.2 (C-2'), 126.47 (C-3'), 126.5 H, 4.47; N, 19.60. Found: C, 58.37; H, 4.41; N, 19.44. 
(E)-2-(( 4'-((E)-(2-(2,4-dichlorophenyl)hydraz?no) 
methy 1)-[ 1, 1 '-biphenyl ]-4-y l)methy lene )hydrazme-1-
carboximidamide hydrochloride (7 Ag) 
NH2 
HNAN.,.N~ 4 
H 
•HCl 
3' 
2' p" 
I~ 
Yield: 80%; mp 356-358° C. 1H NMR (400 MHz, 
DMSO-d6) Ii 7.33 (d, J=8.8 and 2.4 Hz, lH, H-5"), 7.48 (d, 
J=2.4 Hz, lH, H-3"), 7.59 (d, J=8.8 Hz, lH, H-6"), 7.5-8.2 
(br s, 4H, C=HN-NH-C(NH_2) N~ +), 7.77 (s, 4H, 
H-2', H-3', H-5', and H-6'), 7.84 (d, J=8.4 Hz, 2H, H-2 and 
H-6), 7.98 (d, J=8.4 Hz, 2H, H-3 and H-5), 8.22 (s, lH, 
H-CH=N-NH-Ar), 8.35 (s, lH, C 
H=N- NH----C(NH2) NH2 +), 10.12 (s, lH, CH=N-N 
H-Ar), 11.78 (s, lH, CH N-NH_-C(NH2)=NH2 +). 
De NMR (100 MHz, DMSO-d6) Ii 116.7 C-6"), 122.3 
(C-4"), 126.1 (C-2"), 126.75 (C-2), 126.85 (C-2'), 126.97 
(C-3'), 128.1 (C-3), 128.6 (C-3"), 129.4 (C-5"), 133.0 (C-1'), 
134.5 (C-1), 139.6 (C-4'), 140.5 (C-1 "), 
140.6 ~H=NNHAr), 140.7 (C-4), 146.5 
~H NNHC(NH2)=NH2+), 155.2 (CH NNH 
QNH2) NH2 +). The observed CHN combustion analysis 
data (Found: C, 54.96; H, 4.04; N, 17.52 and C, 54.79; H, 
4.19; N, 17.58) did not match pure 7Ag (Calcd: C, 56.40; H, 
4.73; N, 17.16) but was consistent with 3.1% of (2E,2'E)-
2,2'-([1, 1 '-biphenyl]-4,4'-diylbis(methanylylidene ))-bis(hy-
drazine-1-carboximidamide) dihydrochloride1 (3A). 
(E)-2-(1-( 4'-( (E)-1-(2-(2-chlorophenyl)hydrazono) 
ethyl)-[1, 1 '-biphenyl]-4-yl)ethylidene )hydrazine-1-
carboximidamide hydrochloride (8Aa) 
15 (C-1 ), 127.4 (C-5"), 128.2 (C-3), 133.6 (C-1 '), 137 .7 
(C-3"), 139.2 (C-4'), 140.3 (C-4), 141.4 (C-1"), 
147.8 ~(CH3 ) N-NH-Ar), 151.4 ~(CH3)= 
NNHC(NH2)=NH2+), 155.7 (C(CH3 ) NNH 
~(NH2)=NH2+). Anal. Calcd. for C23H24Cl2N6: C, 60.66; 
20 H, 5.31; N, 18.46. Found: C, 60.43; H, 5.28; N, 18.52. 
Bacterial and Fungal Strains. 
The bacterial strains B. subtilis 168 (strain A) was 
obtained from the Bacillus Genetic Stock Center (Ohio State 
University). L. monocytogenes ATCC 19115 (strain B), A. 
25 baumannii ATCC 19606 (strain E), E. coli MC1061 (strain 
G), K. pneumoniae ATCC 27736 (strain H), and S. enterica 
ATCC 14028 (strain J) were gifts from Dr. Paul Hergen-
torther (University of Illinois Champagne-Urbana). MRSA 
(strain C) and VRE (strain D) were obtained from Dr. David 
30 Sherman (University of Michigan). The E. cloacae ATCC 
13047 (strain F) and P. aeruginosa ATCC 27853 (strain I) 
were gifts of Dr. Dev P. Arya (Clemson University). M. 
smegmatis MC2-155 (strain K) was obtained from Dr. 
Sabine Erht (Cornell University). The yeast strains Candida 
35 albicans ATCC 10231, C. albicans ATCC 64124, and C. 
albicans ATCC MYA-2876 were gifts from Dr. Jon Y. 
Takemoto (Utah State University, Logan, Utah, USA). The 
yeast strains C. albicans ATCC MYA-90819, C. albicans 
ATCC MYA-2310, C. albicans ATCC MYA-1237, and C. 
40 albicans ATCC MYA-1003 were obtained from the Ameri-
can Type Culture Collection (ATCC; Manassas, Va., USA). 
Determination of MIC Values for Compounds 3A-B, 
4A,C-H, 7 Aa-Ag, and 8Aa as Antibacterials. 
MIC values were determined against a variety of Gram-
45 positive (strains A-D) and Gram-negative (E-J) bacterial and 
mycobacterial (K) strains using the double-dilution method, 
as previously published. Preliminary screening was per-
formed using 500 µM of each compound. Compounds that 
were found to inhibit the growth of bacteria at 500 µM were 
50 then tested in a range of 0.5 to 250 µM, and bacteria were 
grown at 37° C. in Mueller-Hinton (MH) broth. 
Development of Bacterial Resistance. 
The development of resistance of L. monocytogenes 
ATCC 19115 (strain B), MRSA (strain C), VRE (strain D), 
55 and P. aeruginosa ATCC 27853 (strain I) to compounds 4D, 
4F and 7 Aa as well as AMK as a reference was determined 
b/ following a previously published protocol. The ~acteria 
were grown in MH broth at 37° C. for these expenments. 
Briefly, the lh MIC concentration, from an active MIC 
60 experiments, was diluted 1: 100 and grown overnight at 37° 
C. The resulting cultures were diluted 1: 1000 and grown 
until the culture reached -300,000 cfu/mL. That culture was 
then further diluted 1: 1000 and used to determine the next 
round of MIC values. MIC values were determined every 
65 other day for a total of 15 rounds (Note: for the bacterial 
strains that developed resistance to compounds prior to the 
15 passages, the MIC value determination was discontinued 
US 10,173,968 B2 
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post resistance observation). The fold changes of the MIC 
values were determined and these data are presented in FIG. 
2. 
34 
The confluent cells were trypsinized with 0.05%-trypsin-
0.53 mM EDTA, centrifuged (1,200 rpm) and resuspended 
in fresh medium (Fl2-K or DMEM). The cells were seeded 
into 96-well microtiter plates at a density of 3,000 cells/well Determination of MIC Values for Compounds 3A-B, 
4A,C-H, 7Aa-Ag, and 8Aa as Antifungals. 5 and were grown overnight. The following day, the media 
were replaced by 100 µL of fresh culture media containing 
serially diluted compounds 3A-B, 4A,C-H, and 7Aa-Af, as 
well as a reference compound, AmB, ( at final concentrations 
of0.24-31.2 µg/mL or sterile ddH2 0 (negative control). The 
10 cells were incubated for an additional 24 hat 37° C. with 5% 
In vitro MIC testing was performed according to the CLSI 
M27-A3 standard microbroth dilution methodology for the 
susceptibility testing of yeasts with minor modifications. 
Briefly, serial dilutions of the test compounds as well as a 
reference compound, AmB, were prepared in RPMI 1640 
medium (catalog# R6504, Sigma-Aldrich Chemical Co., St. 
Louis, Mo.) buffered to pH 7 with 0.165 M morpholinepro-
panesulfonic acid (MOPS) buffer (Sigma-Aldrich Chemical 
Co.) using 96-well plates in a range of0.48-31.2 µg/mL, and 
microtiter plates were then incubated at 35° C. for 2 days. 15 
MIC values were read visually for all tested compounds, and 
the endpoint was determined as the minimum concentration 
of compound that yielded complete inhibition relative to 
growth control. 
C02 in a humidified incubator. Each well was treated with 
10 µL (25 µg/mL) ofresazurin sodium salt (Sigma-Aldrich) 
for 3-6 h to determine cell viability. Metabolically active 
cells can convert the blue non-fluorescent dye resazurin to 
the pink and highly fluorescent dye resorufin, which can be 
detected at A560 excitation and A590 emission wavelengths 
by using a SpectraMax MS plate reader. Triton X-100® 
(0.5%, v/v) gave complete loss of cell viability and was used 
Development of Fungal Resistance. 
C. albicans ATCC 10231 was used to perform the devel-
opment of resistance of this strain to compounds 4F and 
20 as the positive control. The percent cell survival was calcu-
lated as: (test value/control value )xl 00, where control value 
represents cells+resazurin-drug, and test value represents 
cells+resazurin+drug. These data are presented in FIGS. 
4A-B. 
7 Aa, as well as AmB as a reference. Firstly, MIC values of 
4F, 7 Aa, and POS against this strain were determined in 
96-well plates using RPMI 1640 medium at 35° C. for 48 h. 25 
Aliquot of 10 µL from the well that was showing the 1h MIC 
values were subcultured into PDA and grown overnight at 
35° C. A single colony was picked to inoculate fresh RPMI 
1640 medium and that culture was used to determine the 
next round of MIC values. The MIC values for each com-
pound were determined every third day for a total of 15 
passages of MIC determination. The fold changes of the 
MIC values were determined and these data are presented in 
FIG. 2. 
Cell-Based [3H]Dofetilide Binding Assay. 
HEK-293 cell membranes which specifically and stably 
express the hERG channel protein were prepared and har-
vested as previously described. Assays were conducted in 
duplicate, and three independent assays were performed for 
30 each compound that was evaluated. Cell membrane suspen-
sion (5 µg) was added to duplicate tubes containing assay 
buffer (50 mM Tris, 10 mM KC!, and 1 mM MgCl2 , pH 7.4), 
25 µL of a single concentration of analogue ( a concentration 
range of 10 nM-100 µM was employed for each experi-
35 ment), and 25 µL of [3 H]dofetilide (5 nM, final concentra-
tion) for an assay volume of 250 µL. Nonspecific binding 
was assessed in the presence of 1 mM amitriptyline. Binding 
occurred for 60 min at 25° C. and was terminated by rapid 
filtration through Whatman GF/B filters, which were pre-
Assays for Reactive Oxygen Species (ROS) Production. 
We used the 2',7'-dichlorodihydrofluorescein diacetate 
(DCFH-DA) dye as a probe to measure the production of 
ROS in yeast cells upon treatment with our compounds. 
DCFH-DA can easily cross the cell membranes and be 
hydrolyzed by cellular esterases to the non-fluorescent 2',7'-
dichlorodihydrofluorescein (DCFH), which can further be 
oxidized to the highly fluorescent 2',7'-dichlorofluorescein 
(DCF) by the intracellular ROS. Five mL of RPMI 1640 
medium were inoculated using a single colony of C. albi-
cans ATCC 10231 (strain A) in a Falcon tube and grown 45 
overnight at 35° C. at 200 rpm. The overnight culture was 
diluted by adding 200 µL of yeast cells to 800 µL of the same 
medium. Cell suspension (100 µL) was added to the RPMI 
1640 medium containing no drug (negative control) or 
compounds 4F and 7Aa at their lx and 2x MIC values, and 50 
treated for 1 h at 35° C. H20 2 at 1 mM was also used as a 
positive control. Cells were centrifuged and washed twice 
with PBS buffer (pH 7.2). Cells were resuspended in the 
same buffer and incubated with DCFH-DA (20 µg/mL) for 
40 soaked in 0.5% PEI for 2 h. Filters were washed three times 
30 min in the dark. Afterwards, cells were centrifuged and 55 
washed with PBS buffer to remove excess DCFH-DA. Glass 
slides with 10-15 µL of each mixture were prepared and 
observed in bright field and fluorescence modes (FITC filter 
set, excitation and emission wavelengths of 488 and 512 nm, 
respectively) using a Zeiss Axovert 200M fluorescence 60 
microscope (FIG. 3). 
Toxicity Studies. 
Cytotoxicity assays were performed as previously 
described. The human lung carcinoma epithelial cells A549 
and the normal human bronchial epithelial cells BEAS-2B 65 
were grown in Fl2-K and DMEM medium containing 10% 
fetal bovine serum (FBS) and 1 % antibiotics, respectively. 
with -1 mL of ice-cold assay buffer. Radioactivity retained 
by the filters was determined by liquid scintillation counting 
by using a Tri-Carb 2100TR liquid scintillation analyzer 
(PerkinElmer Life and Analytical Sciences, Boston, Mass.). 
These data are presented in FIG. 5. 
In summary, amidinohydrazone compounds such as nine 
bis(N-amidino )hydrazones and eight N-amidino-N'-aryl-
bishydrazones were shown to have antifungal activity and 
their activity was not readily predicable from their antibac-
terial activity. In addition, the amidinohydrazone com-
pounds displayed low potential for resistance development, 
and were found to induce ROS production in a C. albicans 
strain. They were also found to display reasonable toxicity 
profiles against two mammalian cell lines as well as only 
moderate, acceptable hERG channel inhibition. In light of 
our SAR study, compounds 4F, 7 Ac, and 7 Af, were pre-
ferred embodiments of the disclosure. 
Only the preferred embodiment of the present invention 
and examples of its versatility are shown and described in 
the present disclosure. It is to be understood that the present 
invention is capable of use in various other combinations 
and environments and is capable of changes or modifications 
within the scope of the inventive concept as expressed 
herein. Thus, for example, those skilled in the art will 
recognize, or be able to ascertain, using no more than routine 
experimentation, numerous equivalents to the specific sub-
stances, procedures and arrangements described herein. 
US 10,173,968 B2 
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Such equivalents are considered to be within the scope of 
this invention, and are covered by the following claims. 
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What is claimed is: 
1. A method for treating a fungal infection, the method 
comprising administering to a subject in need thereof a 
therapeutically effective amount of a compound according to 
formula (I): 30 
(I) 
R R 
R\ }-linker--{ l 35 
HN-N N-NH 
or a pharmaceutically acceptable salt thereof, wherein 
each R is independently H or a lower alkyl, wherein 40 
each R 1 is independently an amidino or a phenyl, and 
wherein the linker is 
38 
3. The method of claim 1, wherein the compound 1s 
according to formula (IV): 
(IV) 
or a pharmaceutically acceptable salt thereof; wherein Ar 
is a phenyl group; wherein each X is independently 
selected from the group consisting of an electron-
withdrawing group selected from the group consisting 
of a halogen, a carbonyl group, sulfoxide, sulfone, 
sulfonate, sulfonamide, a nitro group, a cyano group; 
and wherein each n is independently between O and 5, 
with O representing an unsubstituted phenyl group. 
4. The method of claim 3, wherein each X is indepen-
dently selected from the group consisting of fluorine, chlo-
rine, and bromine. 
5. The method of claim 1, wherein the compound is 
according to formula (V): 
(V) 
or a pharmaceutically acceptable salt thereof; wherein Ar 
is a phenyl group; wherein each X is independently 
selected from the group consisting of an electron-
withdrawing group selected from the group consisting 
of a halogen, a carbonyl group, sulfoxide, sulfone, 
sulfonate, sulfonamide, a nitro group, a cyano group; 
wherein n is between O and 5, with O representing an 
unsubstituted phenyl group; and wherein R2 is selected 
from the group consisting ofH, a lower alkyl, a phenyl, 
a substituted lower alkyl, or a substituted phenyl. 
6. The method of claim 5, wherein each X is indepen-
dently selected from the group consisting of fluorine, chlo-
rine, and bromine. 
7. The method of claim 1, wherein the compound is a 
pharmaceutically acceptable hydrochloride salt. 
45 8. The method of claim 1, wherein the compound is 
or 
( ) ( ) . 
2. The method of claim 1, wherein the compound is 
according to formula (III): 
(III) 
55 
or a pharmaceutically acceptable salt thereof; wherein 
each R2 is independently selected from the group 65 
consisting of H, a lower alkyl, a phenyl, a substituted 
lower alkyl, or a substituted phenyl. 
selected from the group consisting of: 
39 
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